AMR/data-raw/breakpoints_eucast.csv

1		guideline	type	host	method	site	mo	rank_index	ab	ref_tbl	disk_dose	breakpoint_S	breakpoint_R	uti	is_SDD	note
2	1	EUCAST 2026	human	human	DISK	NA	B_ACHRMB_XYLS	2	MEM	A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	26	20	FALSE	FALSE	NA
3	2	EUCAST 2026	human	human	MIC	NA	B_ACHRMB_XYLS	2	MEM	A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)	NA	1	4	FALSE	FALSE	NA
4	3	EUCAST 2026	human	human	DISK	NA	B_ACHRMB_XYLS	2	SXT	A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	26	26	FALSE	FALSE	[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
5	4	EUCAST 2026	human	human	MIC	NA	B_ACHRMB_XYLS	2	SXT	A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
6	5	EUCAST 2026	human	human	DISK	NA	B_ACHRMB_XYLS	2	TZP	A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	26	26	FALSE	FALSE	NA
7	6	EUCAST 2026	human	human	MIC	NA	B_ACHRMB_XYLS	2	TZP	A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
8	7	EUCAST 2026	human	human	DISK	systemic infections	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	19	19	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
9	8	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	19	19	FALSE	FALSE	NA
10	9	EUCAST 2026	human	human	MIC	systemic infections	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
11	10	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
12	11	EUCAST 2026	human	human	DISK	NA	B_ACNTB	3	CIP	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	21	FALSE	FALSE	NA
13	12	EUCAST 2026	human	human	DISK	Topical	B_ACNTB	3	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	FALSE	FALSE	NA
14	13	EUCAST 2026	human	human	MIC	NA	B_ACNTB	3	CIP	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
15	14	EUCAST 2026	human	human	MIC	Topical	B_ACNTB	3	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
16	15	EUCAST 2026	human	human	MIC	NA	B_ACNTB	3	COL	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).
17	16	EUCAST 2026	human	human	MIC	Topical	B_ACNTB	3	COL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
18	17	EUCAST 2026	human	human	DISK	NA	B_ACNTB	3	DOR	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	50	22	FALSE	FALSE	NA
19	18	EUCAST 2026	human	human	MIC	NA	B_ACNTB	3	DOR	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	NA
20	19	EUCAST 2026	human	human	DISK	systemic infections	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
21	20	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	NA
22	21	EUCAST 2026	human	human	DISK	Topical	B_ACNTB	3	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	NA
23	22	EUCAST 2026	human	human	MIC	systemic infections	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
24	23	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
25	24	EUCAST 2026	human	human	MIC	Topical	B_ACNTB	3	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
26	25	EUCAST 2026	human	human	DISK	NA	B_ACNTB	3	IPM	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	21	FALSE	FALSE	NA
27	26	EUCAST 2026	human	human	MIC	NA	B_ACNTB	3	IPM	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	2	4	FALSE	FALSE	NA
28	27	EUCAST 2026	human	human	DISK	NA	B_ACNTB	3	LVX	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	20	FALSE	FALSE	NA
29	28	EUCAST 2026	human	human	DISK	Topical	B_ACNTB	3	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	23	FALSE	FALSE	NA
30	29	EUCAST 2026	human	human	MIC	NA	B_ACNTB	3	LVX	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	1	FALSE	FALSE	NA
31	30	EUCAST 2026	human	human	MIC	Topical	B_ACNTB	3	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
32	31	EUCAST 2026	human	human	DISK	indications other than meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	21	15	FALSE	FALSE	NA
33	32	EUCAST 2026	human	human	DISK	meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	21	21	FALSE	FALSE	NA
34	33	EUCAST 2026	human	human	MIC	indications other than meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	2	8	FALSE	FALSE	NA
35	34	EUCAST 2026	human	human	MIC	meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
36	35	EUCAST 2026	human	human	MIC	Topical	B_ACNTB	3	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
37	36	EUCAST 2026	human	human	DISK	NA	B_ACNTB	3	SXT	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	16	16	FALSE	FALSE	[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
38	37	EUCAST 2026	human	human	MIC	NA	B_ACNTB	3	SXT	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
39	38	EUCAST 2026	human	human	DISK	systemic infections	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
40	39	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	NA
41	40	EUCAST 2026	human	human	DISK	Topical	B_ACNTB	3	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	NA
42	41	EUCAST 2026	human	human	MIC	systemic infections	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
43	42	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
44	43	EUCAST 2026	human	human	MIC	Topical	B_ACNTB	3	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
45	44	EUCAST 2026	human	human	DISK	NA	B_AERCC_SNGN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	26	26	FALSE	FALSE	NA
46	45	EUCAST 2026	human	human	MIC	NA	B_AERCC_SNGN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
47	46	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_AERCC_SNGN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	TRUE	FALSE	[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note
48	47	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_AERCC_SNGN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	TRUE	FALSE	NA
49	48	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_AERCC_SNGN	2	LVX	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	TRUE	FALSE	[1] Susceptibility can be inferred from ciprofloxacin susceptibility.
50	49	EUCAST 2026	human	human	DISK	NA	B_AERCC_SNGN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	31	31	FALSE	FALSE	NA
51	50	EUCAST 2026	human	human	MIC	NA	B_AERCC_SNGN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
52	51	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_AERCC_SNGN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	100 mcg	16	16	TRUE	FALSE	NA
53	52	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_AERCC_SNGN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	TRUE	FALSE	NA
54	53	EUCAST 2026	human	human	DISK	screen only	B_AERCC_SNGN	2	NOR	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.
55	54	EUCAST 2026	human	human	DISK	NA	B_AERCC_SNGN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	1 unit	21	21	FALSE	FALSE	NA
56	55	EUCAST 2026	human	human	MIC	NA	B_AERCC_SNGN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
57	56	EUCAST 2026	human	human	DISK	NA	B_AERCC_SNGN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	25	25	FALSE	FALSE	NA
58	57	EUCAST 2026	human	human	MIC	NA	B_AERCC_SNGN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
59	58	EUCAST 2026	human	human	DISK	NA	B_AERCC_SNGN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	16	16	FALSE	FALSE	[A] Non-wild type isolates were not available when developing the disk diffusion method.
60	59	EUCAST 2026	human	human	MIC	NA	B_AERCC_SNGN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
61	60	EUCAST 2026	human	human	DISK	NA	B_AERCC_URIN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	26	26	FALSE	FALSE	NA
62	61	EUCAST 2026	human	human	MIC	NA	B_AERCC_URIN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
63	62	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_AERCC_URIN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	TRUE	FALSE	[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note
64	63	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_AERCC_URIN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	TRUE	FALSE	NA
65	64	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_AERCC_URIN	2	LVX	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	TRUE	FALSE	[1] Susceptibility can be inferred from ciprofloxacin susceptibility.
66	65	EUCAST 2026	human	human	DISK	NA	B_AERCC_URIN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	31	31	FALSE	FALSE	NA
67	66	EUCAST 2026	human	human	MIC	NA	B_AERCC_URIN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
68	67	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_AERCC_URIN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	100 mcg	16	16	TRUE	FALSE	NA
69	68	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_AERCC_URIN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	TRUE	FALSE	NA
70	69	EUCAST 2026	human	human	DISK	screen only	B_AERCC_URIN	2	NOR	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.
71	70	EUCAST 2026	human	human	DISK	NA	B_AERCC_URIN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	1 unit	21	21	FALSE	FALSE	NA
72	71	EUCAST 2026	human	human	MIC	NA	B_AERCC_URIN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
73	72	EUCAST 2026	human	human	DISK	NA	B_AERCC_URIN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	25	25	FALSE	FALSE	NA
74	73	EUCAST 2026	human	human	MIC	NA	B_AERCC_URIN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
75	74	EUCAST 2026	human	human	DISK	NA	B_AERCC_URIN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	16	16	FALSE	FALSE	[A] Non-wild type isolates were not available when developing the disk diffusion method.
76	75	EUCAST 2026	human	human	MIC	NA	B_AERCC_URIN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
77	76	EUCAST 2026	human	human	DISK	NA	B_AERMN	3	ATM	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	29	26	FALSE	FALSE	NA
78	77	EUCAST 2026	human	human	MIC	NA	B_AERMN	3	ATM	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	NA	1	4	FALSE	FALSE	NA
79	78	EUCAST 2026	human	human	DISK	NA	B_AERMN	3	CAZ	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	21	FALSE	FALSE	NA
80	79	EUCAST 2026	human	human	MIC	NA	B_AERMN	3	CAZ	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	NA	1	4	FALSE	FALSE	NA
81	80	EUCAST 2026	human	human	DISK	NA	B_AERMN	3	CIP	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	27	24	FALSE	FALSE	NA
82	81	EUCAST 2026	human	human	MIC	NA	B_AERMN	3	CIP	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.5	FALSE	FALSE	NA
83	82	EUCAST 2026	human	human	DISK	NA	B_AERMN	3	FEP	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	24	FALSE	FALSE	NA
84	83	EUCAST 2026	human	human	MIC	NA	B_AERMN	3	FEP	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	NA	1	4	FALSE	FALSE	NA
85	84	EUCAST 2026	human	human	DISK	NA	B_AERMN	3	LVX	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	27	24	FALSE	FALSE	NA
86	85	EUCAST 2026	human	human	MIC	NA	B_AERMN	3	LVX	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	1	FALSE	FALSE	NA
87	86	EUCAST 2026	human	human	DISK	NA	B_AERMN	3	SXT	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	16	16	FALSE	FALSE	[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
88	87	EUCAST 2026	human	human	MIC	NA	B_AERMN	3	SXT	Aeromonas (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
89	88	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	CIP	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	23	FALSE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
90	89	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	CIP	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
91	90	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	CLI	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	17	17	FALSE	FALSE	NA
92	91	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	CLI	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
93	92	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	ERY	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	24	24	FALSE	FALSE	NA
94	93	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	ERY	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
95	94	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	IPM	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	30	30	FALSE	FALSE	NA
96	95	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	IPM	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
97	96	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	LNZ	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	22	FALSE	FALSE	NA
98	97	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	LNZ	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
99	98	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	LVX	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	23	FALSE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
100	99	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	LVX	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
101	100	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	MEM	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	25	25	FALSE	FALSE	NA
102	101	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	MEM	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
103	102	EUCAST 2026	human	human	DISK	screen only	B_BCLLS	3	NOR	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	21	21	FALSE	FALSE	[B] | [B] Isolates categorised as screen negative can be reported "susceptible increased exposure" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.
104	103	EUCAST 2026	human	human	DISK	NA	B_BCLLS	3	VAN	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	10	10	FALSE	FALSE	[A] Non-wild type isolates were not available when developing the disk diffusion method.
105	104	EUCAST 2026	human	human	MIC	NA	B_BCLLS	3	VAN	Bacillus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
106	105	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	AMX	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.
107	106	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	CIP	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	24	FALSE	FALSE	NA
108	107	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	CIP	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.25	FALSE	FALSE	NA
109	108	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	CLI	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	17	17	FALSE	FALSE	NA
110	109	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	CLI	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
111	110	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	DOX	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
112	111	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	LNZ	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	20	20	FALSE	FALSE	NA
113	112	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	LNZ	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
114	113	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	LVX	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	23	FALSE	FALSE	NA
115	114	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	LVX	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
116	115	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	PEN	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	1 unit	50	18	FALSE	FALSE	NA
117	116	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	PEN	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
118	117	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	RIF	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	12	12	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
119	118	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	RIF	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
120	119	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	TCY	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	26	26	FALSE	FALSE	NA
121	120	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	TCY	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
122	121	EUCAST 2026	human	human	DISK	NA	B_BCLLS_ANTH	2	VAN	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	10	10	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
123	122	EUCAST 2026	human	human	MIC	NA	B_BCLLS_ANTH	2	VAN	B.anthracis (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
124	123	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	AMC	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	14	14	FALSE	FALSE	NA
125	124	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	AMC	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
126	125	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	10	10	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
127	126	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
128	127	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	23	23	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
129	128	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
130	129	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	NA
131	130	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
132	131	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	28	28	FALSE	FALSE	NA
133	132	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
134	133	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	25	25	FALSE	FALSE	[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
135	134	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
136	135	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	SAM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	25	25	FALSE	FALSE	NA
137	136	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	SAM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
138	137	EUCAST 2026	human	human	DISK	NA	B_BCTRD	3	TZP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	24	24	FALSE	FALSE	[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.
139	138	EUCAST 2026	human	human	MIC	NA	B_BCTRD	3	TZP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.
140	139	EUCAST 2026	human	human	DISK	NA	B_BRCLL_MLTN	2	CIP	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	27	FALSE	FALSE	NA
141	140	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	CIP	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
142	141	EUCAST 2026	human	human	DISK	meningitis	B_BRCLL_MLTN	2	CRO	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	30	30	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
143	142	EUCAST 2026	human	human	MIC	meningitis	B_BRCLL_MLTN	2	CRO	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
144	143	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	DOX	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
145	144	EUCAST 2026	human	human	DISK	NA	B_BRCLL_MLTN	2	GEN	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	23	23	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
146	145	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	GEN	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
147	146	EUCAST 2026	human	human	DISK	NA	B_BRCLL_MLTN	2	LVX	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	28	FALSE	FALSE	NA
148	147	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	LVX	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
149	148	EUCAST 2026	human	human	DISK	NA	B_BRCLL_MLTN	2	RIF	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	20	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.
150	149	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	RIF	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
151	150	EUCAST 2026	human	human	DISK	NA	B_BRCLL_MLTN	2	STR1	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	15	15	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
152	151	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	STR1	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
153	152	EUCAST 2026	human	human	DISK	NA	B_BRCLL_MLTN	2	SXT	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	29	29	FALSE	FALSE	[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
154	153	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	SXT	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
155	154	EUCAST 2026	human	human	DISK	NA	B_BRCLL_MLTN	2	TCY	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	42	42	FALSE	FALSE	NA
156	155	EUCAST 2026	human	human	MIC	NA	B_BRCLL_MLTN	2	TCY	B.melitensis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
157	156	EUCAST 2026	human	human	DISK	NA	B_BRKHL_PSDM	2	AMC	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	20/10 mcg	50	22	FALSE	FALSE	NA
158	157	EUCAST 2026	human	human	MIC	NA	B_BRKHL_PSDM	2	AMC	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
159	158	EUCAST 2026	human	human	DISK	NA	B_BRKHL_PSDM	2	CAZ	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	50	18	FALSE	FALSE	NA
160	159	EUCAST 2026	human	human	MIC	NA	B_BRKHL_PSDM	2	CAZ	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	NA
161	160	EUCAST 2026	human	human	DISK	NA	B_BRKHL_PSDM	2	CHL	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	22	FALSE	FALSE	NA
162	161	EUCAST 2026	human	human	MIC	NA	B_BRKHL_PSDM	2	CHL	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	NA
163	162	EUCAST 2026	human	human	MIC	NA	B_BRKHL_PSDM	2	DOX	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	NA
164	163	EUCAST 2026	human	human	DISK	NA	B_BRKHL_PSDM	2	IPM	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	NA
165	164	EUCAST 2026	human	human	MIC	NA	B_BRKHL_PSDM	2	IPM	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
166	165	EUCAST 2026	human	human	DISK	NA	B_BRKHL_PSDM	2	MEM	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	FALSE	FALSE	NA
167	166	EUCAST 2026	human	human	MIC	NA	B_BRKHL_PSDM	2	MEM	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
168	167	EUCAST 2026	human	human	DISK	NA	B_BRKHL_PSDM	2	SXT	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	50	17	FALSE	FALSE	[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
169	168	EUCAST 2026	human	human	MIC	NA	B_BRKHL_PSDM	2	SXT	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
170	169	EUCAST 2026	human	human	DISK	screen only	B_BRKHL_PSDM	2	TCY	B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[A] Isolates categorised as screen negative can be reported "susceptible increased exposure" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.
171	170	EUCAST 2026	human	human	DISK	NA	B_CMPYL_COLI	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	26	FALSE	FALSE	NA
172	171	EUCAST 2026	human	human	MIC	NA	B_CMPYL_COLI	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
173	172	EUCAST 2026	human	human	DISK	NA	B_CMPYL_COLI	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	18	18	FALSE	FALSE	[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
174	173	EUCAST 2026	human	human	MIC	NA	B_CMPYL_COLI	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
175	174	EUCAST 2026	human	human	DISK	NA	B_CMPYL_COLI	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	30	30	FALSE	FALSE	[A] Susceptibility to doxycycline can be inferred from tetracycline.
176	175	EUCAST 2026	human	human	MIC	NA	B_CMPYL_COLI	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Susceptibility to doxycycline can be inferred from tetracycline.
177	176	EUCAST 2026	human	human	DISK	NA	B_CMPYL_JEJN	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	26	FALSE	FALSE	NA
178	177	EUCAST 2026	human	human	MIC	NA	B_CMPYL_JEJN	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
179	178	EUCAST 2026	human	human	DISK	NA	B_CMPYL_JEJN	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	20	20	FALSE	FALSE	[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
180	179	EUCAST 2026	human	human	MIC	NA	B_CMPYL_JEJN	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
181	180	EUCAST 2026	human	human	DISK	NA	B_CMPYL_JEJN	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	30	30	FALSE	FALSE	[A] Susceptibility to doxycycline can be inferred from tetracycline.
182	181	EUCAST 2026	human	human	MIC	NA	B_CMPYL_JEJN	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Susceptibility to doxycycline can be inferred from tetracycline.
183	182	EUCAST 2026	human	human	MIC	NA	B_CRDDS_DFFC	2	FDX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.
184	183	EUCAST 2026	human	human	MIC	NA	B_CRDDS_DFFC	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
185	184	EUCAST 2026	human	human	MIC	NA	B_CRDDS_DFFC	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.
186	185	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	CIP	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	25	FALSE	FALSE	NA
187	186	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	CIP	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
188	187	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	CLI	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	20	20	FALSE	FALSE	[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.
189	188	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	CLI	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.
190	189	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	LNZ	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	25	25	FALSE	FALSE	NA
191	190	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	LNZ	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
192	191	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	MFX	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	25	25	FALSE	FALSE	NA
193	192	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	MFX	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
194	193	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	PEN	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	1 unit	50	12	FALSE	FALSE	NA
195	194	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	PEN	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
196	195	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	RIF	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	30	30	FALSE	FALSE	NA
197	196	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	RIF	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
198	197	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	TCY	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	24	24	FALSE	FALSE	NA
199	198	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	TCY	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
200	199	EUCAST 2026	human	human	DISK	NA	B_CRYNB	3	VAN	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	17	17	FALSE	FALSE	[A] Non-wild typeisolates were not available when developing the disk diffusion method.
201	200	EUCAST 2026	human	human	MIC	NA	B_CRYNB	3	VAN	Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
202	201	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	AMX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.
203	202	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	24	FALSE	FALSE	NA
204	203	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
205	204	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	CLI	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	15	15	FALSE	FALSE	[1] Wild-type C. ulcerans is less susceptible to clindamycin.
206	205	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	CLI	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Wild-type C. ulcerans is less susceptible to clindamycin.
207	206	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	15	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
208	207	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
209	208	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	DOX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
210	209	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	24	24	FALSE	FALSE	NA
211	210	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
212	211	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	25	25	FALSE	FALSE	NA
213	212	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
214	213	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
215	214	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
216	215	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	1 unit	50	12	FALSE	FALSE	NA
217	216	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
218	217	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	24	24	FALSE	FALSE	NA
219	218	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
220	219	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	23	23	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
221	220	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
222	221	EUCAST 2026	human	human	DISK	NA	B_CRYNB_DPHT	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	24	24	FALSE	FALSE	NA
223	222	EUCAST 2026	human	human	MIC	NA	B_CRYNB_DPHT	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
224	223	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	AMX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.
225	224	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	24	FALSE	FALSE	NA
226	225	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
227	226	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	15	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
228	227	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
229	228	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	DOX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
230	229	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	24	24	FALSE	FALSE	NA
231	230	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
232	231	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	25	25	FALSE	FALSE	NA
233	232	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
234	233	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
235	234	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
236	235	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	1 unit	50	12	FALSE	FALSE	NA
237	236	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
238	237	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	24	24	FALSE	FALSE	NA
239	238	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
240	239	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	23	23	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
241	240	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
242	241	EUCAST 2026	human	human	DISK	NA	B_CRYNB_ULCR	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	24	24	FALSE	FALSE	NA
243	242	EUCAST 2026	human	human	MIC	NA	B_CRYNB_ULCR	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
244	243	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
245	244	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
246	245	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
247	246	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
248	247	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	26	26	FALSE	FALSE	[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
249	248	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
250	249	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	CRO	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
251	250	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	CRO	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
252	251	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	CTX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	26	26	FALSE	FALSE	[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
253	252	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
254	253	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
255	254	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	39	39	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
256	255	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	LNZ	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	34	34	FALSE	FALSE	NA
257	256	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	LNZ	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
258	257	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
259	258	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
260	259	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
261	260	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
262	261	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	NA	33	FALSE	FALSE	NA
263	262	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.
264	263	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_ACNS	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	22	22	FALSE	FALSE	NA
265	264	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_ACNS	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
266	265	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
267	266	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
268	267	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
269	268	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
270	269	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
271	270	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	33	33	FALSE	FALSE	[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
272	271	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
273	272	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	CRO	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	30	30	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
274	273	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	CRO	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
275	274	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	CTX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	24	24	FALSE	FALSE	[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
276	275	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
277	276	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
278	277	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	39	39	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
279	278	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
280	279	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	LNZ	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	28	28	FALSE	FALSE	NA
281	280	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	LNZ	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
282	281	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
283	282	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
284	283	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
285	284	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
286	285	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	32	32	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
287	286	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
288	287	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
289	288	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
290	289	EUCAST 2026	human	human	DISK	NA	B_CTBCTR_AVDM	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	19	19	FALSE	FALSE	NA
291	290	EUCAST 2026	human	human	MIC	NA	B_CTBCTR_AVDM	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
292	291	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_CTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
293	292	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_CTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
294	293	EUCAST 2026	human	human	DISK	NA	B_CTRBC_KOSR	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	18	18	FALSE	FALSE	[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.
295	294	EUCAST 2026	human	human	MIC	NA	B_CTRBC_KOSR	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.
296	295	EUCAST 2026	human	human	DISK	NA	B_CTRDM_INNC	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	19	19	FALSE	FALSE	NA
297	296	EUCAST 2026	human	human	MIC	NA	B_CTRDM_INNC	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
298	297	EUCAST 2026	human	human	DISK	NA	B_CTRDM_INNC	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	21	21	FALSE	FALSE	NA
299	298	EUCAST 2026	human	human	MIC	NA	B_CTRDM_INNC	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
300	299	EUCAST 2026	human	human	MIC	NA	B_CTRDM_INNC	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
301	300	EUCAST 2026	human	human	DISK	NA	B_CTRDM_INNC	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	17	17	FALSE	FALSE	[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
302	301	EUCAST 2026	human	human	MIC	NA	B_CTRDM_INNC	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
303	302	EUCAST 2026	human	human	DISK	NA	B_CTRDM_INNC	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	19	19	FALSE	FALSE	[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
304	303	EUCAST 2026	human	human	MIC	NA	B_CTRDM_INNC	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
305	304	EUCAST 2026	human	human	DISK	NA	B_CTRDM_INNC	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	28	28	FALSE	FALSE	NA
306	305	EUCAST 2026	human	human	MIC	NA	B_CTRDM_INNC	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
307	306	EUCAST 2026	human	human	DISK	NA	B_CTRDM_INNC	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	24	24	FALSE	FALSE	NA
308	307	EUCAST 2026	human	human	MIC	NA	B_CTRDM_INNC	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
309	308	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
310	309	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
311	310	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
312	311	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
313	312	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
314	313	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	19	19	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
315	314	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
316	315	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
317	316	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
318	317	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
319	318	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
320	319	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
321	320	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
322	321	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	16	16	FALSE	FALSE	[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
323	322	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
324	323	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	15	15	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
325	324	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
326	325	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
327	326	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
328	327	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
329	328	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
330	329	EUCAST 2026	human	human	DISK	NA	B_CTRDM_PRFR	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	12	12	FALSE	FALSE	NA
331	330	EUCAST 2026	human	human	MIC	NA	B_CTRDM_PRFR	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
332	331	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	21	21	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
333	332	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
334	333	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	20	20	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
335	334	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
336	335	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
337	336	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	26	26	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
338	337	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
339	338	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	22	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
340	339	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
341	340	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	FALSE	FALSE	[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
342	341	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
343	342	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	21	21	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
344	343	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
345	344	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	26	26	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
346	345	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
347	346	EUCAST 2026	human	human	DISK	NA	B_CTRDM_RMSM	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
348	347	EUCAST 2026	human	human	MIC	NA	B_CTRDM_RMSM	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
349	348	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
350	349	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
351	350	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
352	351	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
353	352	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	24	24	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
354	353	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
355	354	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	26	26	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
356	355	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
357	356	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	31	31	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
358	357	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
359	358	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
360	359	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
361	360	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	FALSE	FALSE	[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
362	361	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
363	362	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	21	21	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
364	363	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
365	364	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	29	29	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
366	365	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
367	366	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
368	367	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
369	368	EUCAST 2026	human	human	DISK	NA	B_CTRDM_SPTC	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	14	14	FALSE	FALSE	NA
370	369	EUCAST 2026	human	human	MIC	NA	B_CTRDM_SPTC	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
371	370	EUCAST 2026	human	human	DISK	NA	B_CTRDM_TRTM	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	15	15	FALSE	FALSE	NA
372	371	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
373	372	EUCAST 2026	human	human	DISK	NA	B_CTRDM_TRTM	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	12	12	FALSE	FALSE	NA
374	373	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
375	374	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
376	375	EUCAST 2026	human	human	DISK	NA	B_CTRDM_TRTM	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	28	28	FALSE	FALSE	NA
377	376	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
378	377	EUCAST 2026	human	human	DISK	NA	B_CTRDM_TRTM	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	FALSE	FALSE	NA
379	378	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
380	379	EUCAST 2026	human	human	DISK	NA	B_CTRDM_TRTM	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	20	FALSE	FALSE	[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
381	380	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
382	381	EUCAST 2026	human	human	DISK	NA	B_CTRDM_TRTM	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	22	22	FALSE	FALSE	NA
383	382	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
384	383	EUCAST 2026	human	human	DISK	NA	B_CTRDM_TRTM	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	13	13	FALSE	FALSE	NA
385	384	EUCAST 2026	human	human	MIC	NA	B_CTRDM_TRTM	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
386	385	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ENTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
387	386	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ENTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
388	387	EUCAST 2026	human	human	DISK	NA	B_ENTRC	3	AMP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	10	10	FALSE	FALSE	[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.
389	388	EUCAST 2026	human	human	MIC	NA	B_ENTRC	3	AMP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
390	389	EUCAST 2026	human	human	MIC	NA	B_ENTRC	3	AMX	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[1] Susceptibility can be inferred from ampicillin.
391	390	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ENTRC	3	AMX	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	TRUE	FALSE	[1] Susceptibility can be inferred from ampicillin.
392	391	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ENTRC	3	CIP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	15	15	TRUE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
393	392	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ENTRC	3	CIP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	TRUE	FALSE	NA
394	393	EUCAST 2026	human	human	DISK	NA	B_ENTRC	3	ERV	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	20 mcg	22	22	FALSE	FALSE	NA
395	394	EUCAST 2026	human	human	MIC	NA	B_ENTRC	3	ERV	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
396	395	EUCAST 2026	human	human	DISK	NA	B_ENTRC	3	LNZ	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	20	20	FALSE	FALSE	NA
397	396	EUCAST 2026	human	human	MIC	NA	B_ENTRC	3	LNZ	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
398	397	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ENTRC	3	LVX	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	15	15	TRUE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
399	398	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ENTRC	3	LVX	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	TRUE	FALSE	NA
400	399	EUCAST 2026	human	human	DISK	screen only	B_ENTRC	3	NOR	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	12	12	FALSE	FALSE	[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.
401	400	EUCAST 2026	human	human	DISK	NA	B_ENTRC	3	TEC	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	16	16	FALSE	FALSE	NA
402	401	EUCAST 2026	human	human	MIC	NA	B_ENTRC	3	TEC	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
403	402	EUCAST 2026	human	human	DISK	NA	B_ENTRC	3	TGC	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	20	20	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
404	403	EUCAST 2026	human	human	MIC	NA	B_ENTRC	3	TGC	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
405	404	EUCAST 2026	human	human	DISK	NA	B_ENTRC	3	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	15	15	FALSE	FALSE	NA
406	405	EUCAST 2026	human	human	MIC	NA	B_ENTRC	3	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
407	406	EUCAST 2026	human	human	DISK	NA	B_ENTRC_FACM	2	QDA	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	22	22	FALSE	FALSE	NA
408	407	EUCAST 2026	human	human	MIC	NA	B_ENTRC_FACM	2	QDA	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
409	408	EUCAST 2026	human	human	DISK	NA	B_ENTRC_FACM	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	12	12	FALSE	FALSE	[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.
410	409	EUCAST 2026	human	human	MIC	NA	B_ENTRC_FACM	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
411	410	EUCAST 2026	human	human	MIC	other indications	B_ENTRC_FCLS	2	AMX	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
412	411	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ENTRC_FCLS	2	GEP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	NA
413	412	EUCAST 2026	human	human	DISK	NA	B_ENTRC_FCLS	2	IPM	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	50	21	FALSE	FALSE	NA
414	413	EUCAST 2026	human	human	MIC	NA	B_ENTRC_FCLS	2	IPM	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	NA
415	414	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ENTRC_FCLS	2	NIT	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	100 mcg	15	15	TRUE	FALSE	NA
416	415	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ENTRC_FCLS	2	NIT	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	64	64	TRUE	FALSE	NA
417	416	EUCAST 2026	human	human	DISK	NA	B_ENTRC_FCLS	2	PIP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	18	FALSE	FALSE	NA
418	417	EUCAST 2026	human	human	MIC	NA	B_ENTRC_FCLS	2	PIP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	NA
419	418	EUCAST 2026	human	human	DISK	NA	B_ENTRC_FCLS	2	TZP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	50	18	FALSE	FALSE	[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.
420	419	EUCAST 2026	human	human	MIC	NA	B_ENTRC_FCLS	2	TZP	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.
421	420	EUCAST 2026	human	human	DISK	NA	B_ENTRC_FCLS	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	12	12	FALSE	FALSE	[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.
422	421	EUCAST 2026	human	human	MIC	NA	B_ENTRC_FCLS	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
423	422	EUCAST 2026	human	human	DISK	NA	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	19	FALSE	FALSE	NA
424	423	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	19	19	TRUE	FALSE	NA
425	424	EUCAST 2026	human	human	MIC	NA	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	NA
426	425	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	NA
427	426	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_ESCHR_COLI	2	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	20	FALSE	FALSE	[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
428	427	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_ESCHR_COLI	2	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
429	428	EUCAST 2026	human	human	MIC	NA	B_ESCHR_COLI	2	DFX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
430	429	EUCAST 2026	human	human	DISK	NA	B_ESCHR_COLI	2	ERV	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	20 mcg	17	17	FALSE	FALSE	NA
431	430	EUCAST 2026	human	human	MIC	NA	B_ESCHR_COLI	2	ERV	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
432	431	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	200 mcg	24	24	FALSE	FALSE	[D] Ignore isolated colonies within the inhibition zone (see pictures below).
433	432	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	200 mcg	24	24	TRUE	FALSE	[D] Ignore isolated colonies within the inhibition zone (see pictures below).
434	433	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.
435	434	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.
436	435	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	GEP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	NA
437	436	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
438	437	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
439	438	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	NIT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	100 mcg	11	11	TRUE	FALSE	NA
440	439	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	NIT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	64	64	TRUE	FALSE	NA
441	440	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	NTR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	15	15	TRUE	FALSE	NA
442	441	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	NTR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	TRUE	FALSE	NA
443	442	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_ESCHR_COLI	2	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	17	FALSE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
444	443	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_ESCHR_COLI	2	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	NA
445	444	EUCAST 2026	human	human	DISK	NA	B_ESCHR_COLI	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	18	18	FALSE	FALSE	[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.
446	445	EUCAST 2026	human	human	MIC	NA	B_ESCHR_COLI	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.
447	446	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	TMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	15	15	TRUE	FALSE	NA
448	447	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	TMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	TRUE	FALSE	NA
449	448	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	21	21	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
450	449	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..
451	450	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	21	21	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
452	451	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
453	452	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
454	453	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	23	23	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
455	454	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
456	455	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
457	456	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
458	457	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	34	34	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
459	458	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
460	459	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	31	31	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
461	460	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
462	461	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	25	25	FALSE	FALSE	[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
463	462	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
464	463	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	20	20	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
465	464	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
466	465	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
467	466	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
468	467	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	30	30	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
469	468	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
470	469	EUCAST 2026	human	human	DISK	NA	B_FNGLD	3	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	20	FALSE	FALSE	NA
471	470	EUCAST 2026	human	human	MIC	NA	B_FNGLD	3	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
472	471	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	AMC	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
473	472	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	AMP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
474	473	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	AMP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
475	474	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	AMX	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
476	475	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	30	30	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
477	476	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
478	477	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
479	478	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
480	479	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	36	36	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
481	480	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
482	481	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
483	482	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
484	483	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	30	30	FALSE	FALSE	[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
485	484	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
486	485	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	PEN	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	1 unit	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
487	486	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	PEN	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
488	487	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	SAM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
489	488	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCLT	2	SAM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
490	489	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCLT	2	TZP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
491	490	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	AMC	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
492	491	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	AMC	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
493	492	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	AMP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
494	493	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	AMP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
495	494	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	AMX	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
496	495	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	30	30	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
497	496	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
498	497	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
499	498	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
500	499	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	36	36	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
501	500	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
502	501	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
503	502	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
504	503	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	30	30	FALSE	FALSE	[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
505	504	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
506	505	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	PEN	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	1 unit	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
507	506	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	PEN	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
508	507	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	SAM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
509	508	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	SAM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
510	509	EUCAST 2026	human	human	DISK	NA	B_FSBCTR_NCRP	2	TZP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
511	510	EUCAST 2026	human	human	MIC	NA	B_FSBCTR_NCRP	2	TZP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
512	511	EUCAST 2026	human	human	MIC	NA	B_HLCBCT_PYLR	2	AMX	H.pylori (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
513	512	EUCAST 2026	human	human	MIC	NA	B_HLCBCT_PYLR	2	CLR	H.pylori (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
514	513	EUCAST 2026	human	human	MIC	NA	B_HLCBCT_PYLR	2	LVX	H.pylori (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
515	514	EUCAST 2026	human	human	MIC	NA	B_HLCBCT_PYLR	2	MTR	H.pylori (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
516	515	EUCAST 2026	human	human	MIC	NA	B_HLCBCT_PYLR	2	RIF	H.pylori (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
517	516	EUCAST 2026	human	human	MIC	NA	B_HLCBCT_PYLR	2	TCY	H.pylori (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
518	517	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	15	15	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
519	518	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	50	15	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
520	519	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
521	520	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
522	521	EUCAST 2026	human	human	DISK	indications other than meningitis	B_HMPHL_INFL	2	AMP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	18	18	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
523	522	EUCAST 2026	human	human	MIC	indications other than meningitis	B_HMPHL_INFL	2	AMP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
524	523	EUCAST 2026	human	human	MIC	indications other than meningitis	B_HMPHL_INFL	2	AMX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
525	524	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	AMX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
526	525	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CFM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	26	26	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
527	526	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CFM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
528	527	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CHL	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	28	28	FALSE	FALSE	[1] For chloramphenicol treatment in meningitis, see table of dosages.
529	528	EUCAST 2026	human	human	DISK	Topical	B_HMPHL_INFL	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	28	28	FALSE	FALSE	NA
530	529	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CHL	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For chloramphenicol treatment in meningitis, see table of dosages.
531	530	EUCAST 2026	human	human	MIC	Topical	B_HMPHL_INFL	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
532	531	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CIP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	32	32	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
533	532	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CIP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
534	533	EUCAST 2026	human	human	MIC	Topical	B_HMPHL_INFL	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
535	534	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CPD	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	26	26	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
536	535	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CPD	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
537	536	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CPT	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
538	537	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CRO	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	32	32	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
539	538	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CRO	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
540	539	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CTB	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	25	25	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
541	540	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CTB	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
542	541	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CTX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	27	27	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
543	542	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CTX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
544	543	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	25	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
545	544	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	27	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
546	545	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	NA
547	546	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
548	547	EUCAST 2026	human	human	DISK	pneumonia	B_HMPHL_INFL	2	CZT	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30/10 mcg	23	23	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.
549	548	EUCAST 2026	human	human	MIC	pneumonia	B_HMPHL_INFL	2	CZT	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[3] See table of dosages for dosing for different indications.
550	549	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	DOR	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	23	23	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
551	550	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	DOR	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
552	551	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	DOX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
553	552	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	ETP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	23	23	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
554	553	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	ETP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
555	554	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	FEP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	28	28	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
556	555	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	FEP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
557	556	EUCAST 2026	human	human	MIC	Topical	B_HMPHL_INFL	2	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
558	557	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	IPM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	20	20	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
559	558	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	IPM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
560	559	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	LVX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	30	30	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
561	560	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	LVX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
562	561	EUCAST 2026	human	human	MIC	Topical	B_HMPHL_INFL	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
563	562	EUCAST 2026	human	human	DISK	indications other than meningitis	B_HMPHL_INFL	2	MEM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	20	20	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
564	563	EUCAST 2026	human	human	MIC	indications other than meningitis	B_HMPHL_INFL	2	MEM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
565	564	EUCAST 2026	human	human	MIC	meningitis	B_HMPHL_INFL	2	MEM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
566	565	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	MFX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	28	28	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
567	566	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	MFX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
568	567	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	MNO	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	24	24	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
569	568	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	MNO	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
570	569	EUCAST 2026	human	human	DISK	screen only	B_HMPHL_INFL	2	NAL	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
571	570	EUCAST 2026	human	human	DISK	Topical	B_HMPHL_INFL	2	NAL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).
572	571	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	OFX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	30	30	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
573	572	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	OFX	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
574	573	EUCAST 2026	human	human	MIC	Topical	B_HMPHL_INFL	2	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
575	574	EUCAST 2026	human	human	DISK	screen only	B_HMPHL_INFL	2	PEN	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	1 unit	12	12	FALSE	FALSE	[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
576	575	EUCAST 2026	human	human	DISK	for prophylaxis only	B_HMPHL_INFL	2	RIF	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	18	18	FALSE	FALSE	NA
577	576	EUCAST 2026	human	human	MIC	for prophylaxis only	B_HMPHL_INFL	2	RIF	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
578	577	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	SAM	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.
579	578	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	SXT	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	23	23	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
580	579	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	SXT	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
581	580	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	TCY	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	25	25	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
582	581	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	TCY	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
583	582	EUCAST 2026	human	human	MIC	Topical	B_HMPHL_INFL	2	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
584	583	EUCAST 2026	human	human	DISK	NA	B_HMPHL_INFL	2	TZP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	27	27	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
585	584	EUCAST 2026	human	human	MIC	NA	B_HMPHL_INFL	2	TZP	H.influenzae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
586	585	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	AMC	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	22	22	FALSE	FALSE	NA
587	586	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	AMP	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[2] Susceptibility can be inferred from benzylpenicillin susceptibility.
588	587	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	AMX	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[2] Susceptibility can be inferred from benzylpenicillin susceptibility.
589	588	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	AZM	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Susceptibility can be inferred from erythromycin susceptibility.
590	589	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	CIP	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	28	28	FALSE	FALSE	NA
591	590	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	CIP	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
592	591	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	CLR	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Susceptibility can be inferred from erythromycin susceptibility.
593	592	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	CRO	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	30	30	FALSE	FALSE	NA
594	593	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	CRO	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
595	594	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	CTX	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	27	27	FALSE	FALSE	NA
596	595	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	CTX	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
597	596	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	CXM	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	29	29	FALSE	FALSE	NA
598	597	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	CXM	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
599	598	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	DOX	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.
600	599	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	ERY	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	20	20	FALSE	FALSE	NA
601	600	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	ERY	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
602	601	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	LVX	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	28	28	FALSE	FALSE	NA
603	602	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	LVX	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
604	603	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	MEM	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	30	30	FALSE	FALSE	NA
605	604	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	MEM	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
606	605	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	PEN	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	1 unit	25	25	FALSE	FALSE	NA
607	606	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	PEN	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
608	607	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	RIF	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	20	FALSE	FALSE	NA
609	608	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	RIF	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
610	609	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	SXT	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	28	28	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
611	610	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	SXT	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
612	611	EUCAST 2026	human	human	DISK	NA	B_KGLLA_KING	2	TCY	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	28	28	FALSE	FALSE	NA
613	612	EUCAST 2026	human	human	MIC	NA	B_KGLLA_KING	2	TCY	K.kingae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
614	613	EUCAST 2026	human	human	DISK	NA	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	19	FALSE	FALSE	NA
615	614	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	19	19	TRUE	FALSE	NA
616	615	EUCAST 2026	human	human	MIC	NA	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	NA
617	616	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	NA
618	617	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_KLBSL	3	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	20	FALSE	FALSE	[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
619	618	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_KLBSL	3	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
620	619	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_KLBSL	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
621	620	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_KLBSL	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
622	621	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_KLBSL	3	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	17	FALSE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
623	622	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_KLBSL	3	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	NA
624	623	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_KLBSL	3	TMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	15	15	TRUE	FALSE	NA
625	624	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_KLBSL	3	TMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	TRUE	FALSE	NA
626	625	EUCAST 2026	human	human	DISK	all indications	B_LISTR_MNCY	2	AMP	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	16	16	FALSE	FALSE	NA
627	626	EUCAST 2026	human	human	MIC	all indications	B_LISTR_MNCY	2	AMP	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
628	627	EUCAST 2026	human	human	DISK	indications other than meningitis	B_LISTR_MNCY	2	ERY	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	25	25	FALSE	FALSE	NA
629	628	EUCAST 2026	human	human	MIC	indications other than meningitis	B_LISTR_MNCY	2	ERY	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
630	629	EUCAST 2026	human	human	DISK	all indications	B_LISTR_MNCY	2	MEM	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	26	26	FALSE	FALSE	NA
631	630	EUCAST 2026	human	human	MIC	all indications	B_LISTR_MNCY	2	MEM	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
632	631	EUCAST 2026	human	human	DISK	indications other than meningitis	B_LISTR_MNCY	2	PEN	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	1 unit	13	13	FALSE	FALSE	NA
633	632	EUCAST 2026	human	human	MIC	indications other than meningitis	B_LISTR_MNCY	2	PEN	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
634	633	EUCAST 2026	human	human	DISK	all indications	B_LISTR_MNCY	2	SXT	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	29	29	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
635	634	EUCAST 2026	human	human	MIC	all indications	B_LISTR_MNCY	2	SXT	L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
636	635	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	AMC	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	19	19	FALSE	FALSE	NA
637	636	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	AMC	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
638	637	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	AZM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
639	638	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	CFM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	FALSE	FALSE	NA
640	639	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	CFM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
641	640	EUCAST 2026	human	human	DISK	Topical	B_MRXLL_CTRR	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	31	31	FALSE	FALSE	NA
642	641	EUCAST 2026	human	human	MIC	Topical	B_MRXLL_CTRR	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
643	642	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	CIP	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	31	31	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
644	643	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	CIP	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
645	644	EUCAST 2026	human	human	MIC	Topical	B_MRXLL_CTRR	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
646	645	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	CLR	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
647	646	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	CRO	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	24	21	FALSE	FALSE	NA
648	647	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	CRO	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	NA
649	648	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	CTX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	17	FALSE	FALSE	NA
650	649	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	CTX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	NA
651	650	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	21	18	FALSE	FALSE	NA
652	651	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	21	FALSE	FALSE	NA
653	652	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	4	8	FALSE	FALSE	NA
654	653	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	NA
655	654	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	DOR	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	30	30	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
656	655	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	DOR	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
657	656	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	DOX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
658	657	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	ERY	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	23	23	FALSE	FALSE	[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
659	658	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	ERY	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
660	659	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	ETP	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
661	660	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	ETP	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
662	661	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	FEP	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	20	20	FALSE	FALSE	NA
663	662	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	FEP	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
664	663	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	IPM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
665	664	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	IPM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
666	665	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	LVX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	29	29	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
667	666	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	LVX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
668	667	EUCAST 2026	human	human	MIC	Topical	B_MRXLL_CTRR	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
669	668	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	MEM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	33	33	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
670	669	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	MEM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
671	670	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	MFX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	26	26	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
672	671	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	MFX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
673	672	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	MNO	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	25	25	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
674	673	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	MNO	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
675	674	EUCAST 2026	human	human	DISK	screen only	B_MRXLL_CTRR	2	NAL	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
676	675	EUCAST 2026	human	human	DISK	Topical	B_MRXLL_CTRR	2	NAL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).
677	676	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	OFX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	28	28	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
678	677	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	OFX	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
679	678	EUCAST 2026	human	human	MIC	Topical	B_MRXLL_CTRR	2	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
680	679	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	RXT	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
681	680	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	SAM	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.
682	681	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	SXT	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	15	15	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
683	682	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	SXT	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
684	683	EUCAST 2026	human	human	DISK	NA	B_MRXLL_CTRR	2	TCY	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	26	26	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
685	684	EUCAST 2026	human	human	MIC	NA	B_MRXLL_CTRR	2	TCY	M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
686	685	EUCAST 2026	human	human	MIC	NA	B_MYCBC_TBRC	2	BDQ	M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] For bedaquiline, breakpoints were determined using the EUCAST reference method.
687	686	EUCAST 2026	human	human	MIC	NA	B_MYCBC_TBRC	2	DLM	M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. 3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods.
688	687	EUCAST 2026	human	human	MIC	NA	B_NESSR_GNRR	2	CFM	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
689	688	EUCAST 2026	human	human	MIC	NA	B_NESSR_GNRR	2	CIP	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.06	FALSE	FALSE	NA
690	689	EUCAST 2026	human	human	MIC	NA	B_NESSR_GNRR	2	CRO	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
691	690	EUCAST 2026	human	human	MIC	NA	B_NESSR_GNRR	2	CTX	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
692	691	EUCAST 2026	human	human	MIC	NA	B_NESSR_GNRR	2	OFX	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.25	FALSE	FALSE	NA
693	692	EUCAST 2026	human	human	MIC	surrogate agent	B_NESSR_GNRR	2	PEN	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	1	FALSE	FALSE	[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).
694	693	EUCAST 2026	human	human	MIC	NA	B_NESSR_GNRR	2	SPT	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	64	64	FALSE	FALSE	NA
695	694	EUCAST 2026	human	human	MIC	NA	B_NESSR_GNRR	2	TCY	N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
696	695	EUCAST 2026	human	human	MIC	indications other than meningitis	B_NESSR_MNNG	2	AMP	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	1	FALSE	FALSE	NA
697	696	EUCAST 2026	human	human	MIC	indications other than meningitis	B_NESSR_MNNG	2	AMX	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	1	FALSE	FALSE	NA
698	697	EUCAST 2026	human	human	MIC	meningitis	B_NESSR_MNNG	2	CHL	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For chloramphenicol treatment in meningitis, see table of dosages.
699	698	EUCAST 2026	human	human	MIC	all indications, including meningitis and prophylaxis	B_NESSR_MNNG	2	CIP	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.016	0.016	FALSE	FALSE	NA
700	699	EUCAST 2026	human	human	MIC	all indications including prophylaxis	B_NESSR_MNNG	2	CRO	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
701	700	EUCAST 2026	human	human	MIC	all indications	B_NESSR_MNNG	2	CTX	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
702	701	EUCAST 2026	human	human	MIC	all indications	B_NESSR_MNNG	2	MEM	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.
703	702	EUCAST 2026	human	human	MIC	prophylaxis only	B_NESSR_MNNG	2	MNO	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.
704	703	EUCAST 2026	human	human	MIC	all indications	B_NESSR_MNNG	2	PEN	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
705	704	EUCAST 2026	human	human	MIC	prophylaxis only	B_NESSR_MNNG	2	RIF	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
706	705	EUCAST 2026	human	human	MIC	screen only	B_NESSR_MNNG	2	TCY	N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.
707	706	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
708	707	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	21	21	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
709	708	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
710	709	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
711	710	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	15	15	FALSE	FALSE	[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
712	711	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
713	712	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	32	32	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
714	713	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
715	714	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	37	37	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
716	715	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
717	716	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
718	717	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
719	718	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	19	19	FALSE	FALSE	[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
720	719	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
721	720	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	18	18	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
722	721	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
723	722	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	29	29	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
724	723	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	36	36	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
725	724	EUCAST 2026	human	human	DISK	NA	B_PPTNP	3	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	FALSE	FALSE	NA
726	725	EUCAST 2026	human	human	MIC	NA	B_PPTNP	3	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
727	726	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	22	22	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
728	727	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..
729	728	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
730	729	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
731	730	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
732	731	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	17	17	FALSE	FALSE	[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
733	732	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
734	733	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
735	734	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
736	735	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	36	36	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
737	736	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
738	737	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	30	30	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
739	738	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
740	739	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	22	22	FALSE	FALSE	[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
741	740	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[7] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
742	741	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	20	20	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
743	742	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
744	743	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	31	31	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
745	744	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
746	745	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	32	32	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
747	746	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
748	747	EUCAST 2026	human	human	DISK	NA	B_PPTST_ANRB	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	15	15	FALSE	FALSE	NA
749	748	EUCAST 2026	human	human	MIC	NA	B_PPTST_ANRB	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
750	749	EUCAST 2026	human	human	DISK	NA	B_PROTS_MRBL	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	19	FALSE	FALSE	NA
751	750	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_PROTS_MRBL	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	19	19	TRUE	FALSE	NA
752	751	EUCAST 2026	human	human	MIC	NA	B_PROTS_MRBL	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	NA
753	752	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_PROTS_MRBL	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	NA
754	753	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_PROTS_MRBL	2	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
755	754	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_PROTS_MRBL	2	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
756	755	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_PROTS_MRBL	2	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	17	FALSE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
757	756	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_PROTS_MRBL	2	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	NA
758	757	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	AMC	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
759	758	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	29	29	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
760	759	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	AMP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
761	760	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	AMX	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
762	761	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	18	18	FALSE	FALSE	[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
763	762	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	CLI	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.
764	763	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
765	764	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	ETP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
766	765	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	40	40	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
767	766	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	IPM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
768	767	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	36	36	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
769	768	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	MEM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
770	769	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	28	28	FALSE	FALSE	[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
771	770	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	MTR	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
772	771	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	1 unit	31	31	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
773	772	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	PEN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
774	773	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	SAM	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	36	36	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
775	774	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	TZP	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
776	775	EUCAST 2026	human	human	DISK	NA	B_PRVMN_MICR	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	19	19	FALSE	FALSE	NA
777	776	EUCAST 2026	human	human	MIC	NA	B_PRVMN_MICR	2	VAN	Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
778	777	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	AMC	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
779	778	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	AMP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
780	779	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	AMP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
781	780	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	AMX	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
782	781	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	31	31	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
783	782	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	CLI	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
784	783	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	29	29	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
785	784	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	ETP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
786	785	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
787	786	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	IPM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
788	787	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	34	34	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
789	788	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	MEM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
790	789	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	22	22	FALSE	FALSE	[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
791	790	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	MTR	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.
792	791	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	PEN	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	1 unit	20	20	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
793	792	EUCAST 2026	human	human	MIC	NA	B_PRVTL	3	PEN	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
794	793	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	SAM	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
795	794	EUCAST 2026	human	human	DISK	NA	B_PRVTL	3	TZP	Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	26	26	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
796	795	EUCAST 2026	human	human	DISK	systemic infections	B_PSDMN	3	AMK	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	15	15	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
797	796	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_PSDMN	3	AMK	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	15	15	FALSE	FALSE	NA
798	797	EUCAST 2026	human	human	MIC	systemic infections	B_PSDMN	3	AMK	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
799	798	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_PSDMN	3	AMK	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	FALSE	FALSE	NA
800	799	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	ATM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	18	FALSE	FALSE	NA
801	800	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	ATM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	NA
802	801	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	CAZ	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	50	17	FALSE	FALSE	NA
803	802	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	CAZ	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	NA
804	803	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	CIP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	26	FALSE	FALSE	NA
805	804	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	CIP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
806	805	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	COL	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).
807	806	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	DOR	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	50	22	FALSE	FALSE	NA
808	807	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	DOR	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	NA
809	808	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	FEP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	21	FALSE	FALSE	NA
810	809	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	FEP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	NA
811	810	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	IPM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	50	20	FALSE	FALSE	NA
812	811	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	IPM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	NA
813	812	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	LVX	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	18	FALSE	FALSE	NA
814	813	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	LVX	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	NA
815	814	EUCAST 2026	human	human	DISK	indications other than meningitis	B_PSDMN	3	MEM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	18	FALSE	FALSE	NA
816	815	EUCAST 2026	human	human	MIC	indications other than meningitis	B_PSDMN	3	MEM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	2	8	FALSE	FALSE	NA
817	816	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	PIP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	18	FALSE	FALSE	NA
818	817	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	PIP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	NA
819	818	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	TCC	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	75/10 mcg	50	18	FALSE	FALSE	NA
820	819	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	TCC	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
821	820	EUCAST 2026	human	human	DISK	systemic infections	B_PSDMN	3	TOB	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	18	18	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
822	821	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_PSDMN	3	TOB	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	18	18	FALSE	FALSE	NA
823	822	EUCAST 2026	human	human	MIC	systemic infections	B_PSDMN	3	TOB	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
824	823	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_PSDMN	3	TOB	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
825	824	EUCAST 2026	human	human	DISK	NA	B_PSDMN	3	TZP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	50	18	FALSE	FALSE	NA
826	825	EUCAST 2026	human	human	MIC	NA	B_PSDMN	3	TZP	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	16	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
827	826	EUCAST 2026	human	human	DISK	Topical	B_PSDMN_AERG	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	26	26	FALSE	FALSE	NA
828	827	EUCAST 2026	human	human	MIC	Topical	B_PSDMN_AERG	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
829	828	EUCAST 2026	human	human	MIC	Topical	B_PSDMN_AERG	2	COL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
830	829	EUCAST 2026	human	human	DISK	NA	B_PSDMN_AERG	2	CZA	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10/4 mcg	17	17	FALSE	FALSE	NA
831	830	EUCAST 2026	human	human	MIC	NA	B_PSDMN_AERG	2	CZA	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.
832	831	EUCAST 2026	human	human	DISK	NA	B_PSDMN_AERG	2	CZT	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30/10 mcg	23	23	FALSE	FALSE	[4] See table of dosages for dosing for different indications.
833	832	EUCAST 2026	human	human	MIC	NA	B_PSDMN_AERG	2	CZT	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.
834	833	EUCAST 2026	human	human	DISK	NA	B_PSDMN_AERG	2	FDC	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	22	22	FALSE	FALSE	NA
835	834	EUCAST 2026	human	human	MIC	NA	B_PSDMN_AERG	2	FDC	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.
836	835	EUCAST 2026	human	human	DISK	Topical	B_PSDMN_AERG	2	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	15	15	FALSE	FALSE	NA
837	836	EUCAST 2026	human	human	MIC	Topical	B_PSDMN_AERG	2	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
838	837	EUCAST 2026	human	human	DISK	NA	B_PSDMN_AERG	2	IMR	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10/25 mcg	22	22	FALSE	FALSE	NA
839	838	EUCAST 2026	human	human	MIC	NA	B_PSDMN_AERG	2	IMR	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.
840	839	EUCAST 2026	human	human	DISK	Topical	B_PSDMN_AERG	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	18	18	FALSE	FALSE	NA
841	840	EUCAST 2026	human	human	MIC	Topical	B_PSDMN_AERG	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
842	841	EUCAST 2026	human	human	DISK	indications other than meningitis	B_PSDMN_AERG	2	MEM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	20	14	FALSE	FALSE	NA
843	842	EUCAST 2026	human	human	DISK	meningitis	B_PSDMN_AERG	2	MEM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	20	20	FALSE	FALSE	NA
844	843	EUCAST 2026	human	human	MIC	indications other than meningitis	B_PSDMN_AERG	2	MEM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	2	8	FALSE	FALSE	NA
845	844	EUCAST 2026	human	human	MIC	meningitis	B_PSDMN_AERG	2	MEM	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
846	845	EUCAST 2026	human	human	DISK	NA	B_PSDMN_AERG	2	MEV	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	20/10 mcg	14	14	FALSE	FALSE	NA
847	846	EUCAST 2026	human	human	MIC	NA	B_PSDMN_AERG	2	MEV	Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.
848	847	EUCAST 2026	human	human	MIC	Topical	B_PSDMN_AERG	2	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
849	848	EUCAST 2026	human	human	DISK	Topical	B_PSDMN_AERG	2	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	18	18	FALSE	FALSE	NA
850	849	EUCAST 2026	human	human	MIC	Topical	B_PSDMN_AERG	2	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
851	850	EUCAST 2026	human	human	DISK	NA	B_PSTRL	3	AMC	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	2/1 mcg	15	15	FALSE	FALSE	NA
852	851	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	AMC	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
853	852	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	AMP	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
854	853	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	AMX	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
855	854	EUCAST 2026	human	human	DISK	NA	B_PSTRL	3	CIP	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	27	27	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.
856	855	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	CIP	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
857	856	EUCAST 2026	human	human	DISK	NA	B_PSTRL	3	CTX	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	26	26	FALSE	FALSE	NA
858	857	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	CTX	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
859	858	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	DOX	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
860	859	EUCAST 2026	human	human	DISK	NA	B_PSTRL	3	LVX	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	27	27	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.
861	860	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	LVX	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
862	861	EUCAST 2026	human	human	DISK	screen only	B_PSTRL	3	NAL	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
863	862	EUCAST 2026	human	human	DISK	NA	B_PSTRL	3	PEN	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	1 unit	17	17	FALSE	FALSE	NA
864	863	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	PEN	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
865	864	EUCAST 2026	human	human	DISK	NA	B_PSTRL	3	SXT	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	23	23	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
866	865	EUCAST 2026	human	human	MIC	NA	B_PSTRL	3	SXT	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
867	866	EUCAST 2026	human	human	DISK	screen only	B_PSTRL	3	TCY	Pasteurella (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	24	24	FALSE	FALSE	[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.
868	867	EUCAST 2026	human	human	DISK	NA	B_SERRT	3	SXT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	50	15	FALSE	FALSE	[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
869	868	EUCAST 2026	human	human	MIC	NA	B_SERRT	3	SXT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
870	869	EUCAST 2026	human	human	MIC	NA	B_SLMNL	3	CIP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.
871	870	EUCAST 2026	human	human	DISK	NA	B_STNTR_MLTP	2	SXT	S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	50	16	FALSE	FALSE	[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
872	871	EUCAST 2026	human	human	MIC	NA	B_STNTR_MLTP	2	SXT	S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
873	872	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	AZM	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
874	873	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	CLI	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	22	22	FALSE	FALSE	[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy".
875	874	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	CLI	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy".
876	875	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	CLR	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
877	876	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	DAL	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.
878	877	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	DOX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
879	878	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	ERY	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	21	21	FALSE	FALSE	[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
880	879	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	ERY	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
881	880	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	FUS	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	FALSE	FALSE	NA
882	881	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	FUS	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
883	882	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	LNZ	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	21	21	FALSE	FALSE	NA
884	883	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	LNZ	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
885	884	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	MNO	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
886	885	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	MNO	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
887	886	EUCAST 2026	human	human	DISK	screen only	B_STPHY	3	NOR	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and "susceptible increased exposure" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
888	887	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	QDA	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	21	21	FALSE	FALSE	NA
889	888	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	QDA	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
890	889	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	RXT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
891	890	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	SXT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	24	24	FALSE	FALSE	[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
892	891	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	SXT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
893	892	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	TCY	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	22	22	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
894	893	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	TCY	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
895	894	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	TGC	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	19	19	FALSE	FALSE	[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
896	895	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	TGC	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
897	896	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_STPHY	3	TMP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	19	19	TRUE	FALSE	NA
898	897	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_STPHY	3	TMP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	TRUE	FALSE	NA
899	898	EUCAST 2026	human	human	DISK	NA	B_STPHY	3	TZD	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	20	20	FALSE	FALSE	[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.
900	899	EUCAST 2026	human	human	MIC	NA	B_STPHY	3	TZD	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.
901	900	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	AMK	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	15	15	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
902	901	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	AMK	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
903	902	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	BPR	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	17	17	FALSE	FALSE	[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.
904	903	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	BPR	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.
905	904	EUCAST 2026	human	human	DISK	Topical	B_STPHY_AURS	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	18	18	FALSE	FALSE	NA
906	905	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	FALSE	FALSE	NA
907	906	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	CIP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	17	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
908	907	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	CIP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
909	908	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
910	909	EUCAST 2026	human	human	DISK	indications other than pneumonia	B_STPHY_AURS	2	CPT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	17	FALSE	FALSE	[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.
911	910	EUCAST 2026	human	human	DISK	pneumonia	B_STPHY_AURS	2	CPT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	20	FALSE	FALSE	[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.
912	911	EUCAST 2026	human	human	MIC	indications other than pneumonia	B_STPHY_AURS	2	CPT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.
913	912	EUCAST 2026	human	human	MIC	pneumonia	B_STPHY_AURS	2	CPT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.
914	913	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	DAP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
915	914	EUCAST 2026	human	human	MIC	community-acquired pneumonia	B_STPHY_AURS	2	DFX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.016	0.016	FALSE	FALSE	NA
916	915	EUCAST 2026	human	human	MIC	skin and skin structure infections	B_STPHY_AURS	2	DFX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
917	916	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	ERV	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	20 mcg	20	20	FALSE	FALSE	[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.
918	917	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	ERV	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
919	918	EUCAST 2026	human	human	DISK	screen only	B_STPHY_AURS	2	FOX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	22	22	FALSE	FALSE	[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.
920	919	EUCAST 2026	human	human	DISK	Topical	B_STPHY_AURS	2	FUS	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	23	23	FALSE	FALSE	NA
921	920	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	FUS	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
922	921	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	GEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	18	18	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
923	922	EUCAST 2026	human	human	DISK	Topical	B_STPHY_AURS	2	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	18	18	FALSE	FALSE	NA
924	923	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	GEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
925	924	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
926	925	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	LMU	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	23	FALSE	FALSE	NA
927	926	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	LMU	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
928	927	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	LVX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	22	FALSE	FALSE	[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
929	928	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	LVX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
930	929	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
931	930	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	MFX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	25	25	FALSE	FALSE	[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.
932	931	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	MFX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.
933	932	EUCAST 2026	human	human	DISK	Topical	B_STPHY_AURS	2	MUP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	200 mcg	30	30	FALSE	FALSE	[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
934	933	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	MUP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.
935	934	EUCAST 2026	human	human	DISK	Topical	B_STPHY_AURS	2	NEO	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	14	14	FALSE	FALSE	NA
936	935	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	NEO	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
937	936	EUCAST 2026	human	human	DISK	Topical	B_STPHY_AURS	2	NOR	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).
938	937	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
939	938	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	ORI	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.
940	939	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	PEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	1 unit	26	26	FALSE	FALSE	[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a "cliff"), then report resistant. If not sharp (reduction of growth towards zone edge, like a "beach"), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.
941	940	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	PEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.
942	941	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	RIF	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	26	26	FALSE	FALSE	NA
943	942	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	RIF	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
944	943	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	RTP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
945	944	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	TEC	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
946	945	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	TLV	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.
947	946	EUCAST 2026	human	human	DISK	NA	B_STPHY_AURS	2	TOB	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	18	18	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
948	947	EUCAST 2026	human	human	DISK	Topical	B_STPHY_AURS	2	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	18	18	FALSE	FALSE	NA
949	948	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	TOB	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
950	949	EUCAST 2026	human	human	MIC	Topical	B_STPHY_AURS	2	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
951	950	EUCAST 2026	human	human	MIC	NA	B_STPHY_AURS	2	VAN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
952	951	EUCAST 2026	human	human	DISK	screen only	B_STPHY_CGLN	2	OXA	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	1 mcg	20	20	FALSE	FALSE	[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.
953	952	EUCAST 2026	human	human	DISK	NA	B_STPHY_CONS	2.5	AMK	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	15	15	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
954	953	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	AMK	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
955	954	EUCAST 2026	human	human	DISK	NA	B_STPHY_CONS	2.5	CIP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	22	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
956	955	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	CIP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
957	956	EUCAST 2026	human	human	DISK	screen only	B_STPHY_CONS	2.5	FOX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	22	22	FALSE	FALSE	[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.
958	957	EUCAST 2026	human	human	DISK	NA	B_STPHY_CONS	2.5	GEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	22	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
959	958	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	GEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
960	959	EUCAST 2026	human	human	DISK	NA	B_STPHY_CONS	2.5	LVX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	24	FALSE	FALSE	[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
961	960	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	LVX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	1	FALSE	FALSE	NA
962	961	EUCAST 2026	human	human	DISK	NA	B_STPHY_CONS	2.5	MFX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	28	28	FALSE	FALSE	[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.
963	962	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	MFX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.
964	963	EUCAST 2026	human	human	DISK	NA	B_STPHY_CONS	2.5	RIF	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	30	30	FALSE	FALSE	NA
965	964	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	RIF	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
966	965	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	TEC	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
967	966	EUCAST 2026	human	human	DISK	NA	B_STPHY_CONS	2.5	TOB	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	20	20	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
968	967	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	TOB	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
969	968	EUCAST 2026	human	human	MIC	NA	B_STPHY_CONS	2.5	VAN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
970	969	EUCAST 2026	human	human	DISK	screen only	B_STPHY_EPDR	2	FOX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	27	FALSE	FALSE	[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.
971	970	EUCAST 2026	human	human	DISK	screen only	B_STPHY_INTR	2	OXA	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	1 mcg	20	20	FALSE	FALSE	[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.
972	971	EUCAST 2026	human	human	DISK	screen only	B_STPHY_LGDN	2	FOX	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	27	FALSE	FALSE	[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.
973	972	EUCAST 2026	human	human	DISK	NA	B_STPHY_LGDN	2	PEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	1 unit	26	26	FALSE	FALSE	NA
974	973	EUCAST 2026	human	human	MIC	NA	B_STPHY_LGDN	2	PEN	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
975	974	EUCAST 2026	human	human	DISK	screen only	B_STPHY_PSDN	2	OXA	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	1 mcg	20	20	FALSE	FALSE	[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.
976	975	EUCAST 2026	human	human	DISK	screen only	B_STPHY_SCHL	2	OXA	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	1 mcg	20	20	FALSE	FALSE	[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.
977	976	EUCAST 2026	human	human	DISK	NA	B_STPHY_SPRP	2	AMP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	18	18	FALSE	FALSE	[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).
978	977	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_STPHY_SPRP	2	GEP	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	TRUE	FALSE	NA
979	978	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_STPHY_SPRP	2	NIT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	100 mcg	13	13	TRUE	FALSE	NA
980	979	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_STPHY_SPRP	2	NIT	Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)	NA	64	64	TRUE	FALSE	NA
981	980	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	AZM	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and
982	981	EUCAST 2026	human	human	DISK	Topical	B_STRPT_ABCG	2.5	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	21	21	FALSE	FALSE	NA
983	982	EUCAST 2026	human	human	MIC	Topical	B_STRPT_ABCG	2.5	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
984	983	EUCAST 2026	human	human	MIC	Topical	B_STRPT_ABCG	2.5	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
985	984	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	CLI	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	17	17	FALSE	FALSE	[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.
986	985	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	CLI	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.
987	986	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	CLR	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and
988	987	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	DAL	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
989	988	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	DAP	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
990	989	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	DFX	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
991	990	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	DOX	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
992	991	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	ERY	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	21	21	FALSE	FALSE	[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and
993	992	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	ERY	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and
994	993	EUCAST 2026	human	human	MIC	Topical	B_STRPT_ABCG	2.5	FUS	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	32	32	FALSE	FALSE	NA
995	994	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	LNZ	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	19	19	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
996	995	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	LNZ	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
997	996	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	LVX	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	17	FALSE	FALSE	[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
998	997	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	LVX	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	NA
999	998	EUCAST 2026	human	human	MIC	Topical	B_STRPT_ABCG	2.5	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1000	999	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	MFX	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	19	19	FALSE	FALSE	[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1001	1000	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	MFX	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1002	1001	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	MNO	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1003	1002	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	MNO	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1004	1003	EUCAST 2026	human	human	MIC	Topical	B_STRPT_ABCG	2.5	MUP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1005	1004	EUCAST 2026	human	human	DISK	screen only	B_STRPT_ABCG	2.5	NOR	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	12	12	FALSE	FALSE	[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as "susceptible increased exposure" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
1006	1005	EUCAST 2026	human	human	DISK	Topical	B_STRPT_ABCG	2.5	NOR	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	12	12	FALSE	FALSE	[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).
1007	1006	EUCAST 2026	human	human	MIC	Topical	B_STRPT_ABCG	2.5	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
1008	1007	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	ORI	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1009	1008	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	PEN	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	1 unit	23	23	FALSE	FALSE	NA
1010	1009	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	PEN	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
1011	1010	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	RIF	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	FALSE	FALSE	NA
1012	1011	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	RIF	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1013	1012	EUCAST 2026	human	human	MIC	Topical	B_STRPT_ABCG	2.5	RTP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
1014	1013	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	RXT	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and
1015	1014	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	SXT	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	16	16	FALSE	FALSE	[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1016	1015	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	SXT	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1017	1016	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	TCY	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1018	1017	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	TCY	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1019	1018	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	TEC	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	15	15	FALSE	FALSE	[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1020	1019	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	TEC	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1021	1020	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	TGC	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	19	19	FALSE	FALSE	[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1022	1021	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	TGC	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1023	1022	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	TZD	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	18	18	FALSE	FALSE	[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1024	1023	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	TZD	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1025	1024	EUCAST 2026	human	human	DISK	NA	B_STRPT_ABCG	2.5	VAN	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	13	13	FALSE	FALSE	[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1026	1025	EUCAST 2026	human	human	MIC	NA	B_STRPT_ABCG	2.5	VAN	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1027	1026	EUCAST 2026	human	human	MIC	NA	B_STRPT_ANGN_ANGN	1	DAL	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1028	1027	EUCAST 2026	human	human	MIC	NA	B_STRPT_ANGN_ANGN	1	DFX	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.03	0.03	FALSE	FALSE	NA
1029	1028	EUCAST 2026	human	human	MIC	NA	B_STRPT_ANGN_ANGN	1	ORI	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1030	1029	EUCAST 2026	human	human	DISK	NA	B_STRPT_ANGN_ANGN	1	TZD	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	18	18	FALSE	FALSE	NA
1031	1030	EUCAST 2026	human	human	MIC	NA	B_STRPT_ANGN_ANGN	1	TZD	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1032	1031	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_STRPT_GRPB	2.5	NIT	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	100 mcg	15	15	TRUE	FALSE	NA
1033	1032	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_STRPT_GRPB	2.5	NIT	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	64	64	TRUE	FALSE	NA
1034	1033	EUCAST 2026	human	human	DISK	NA	B_STRPT_GRPB	2.5	PEN	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	1 unit	18	18	FALSE	FALSE	NA
1035	1034	EUCAST 2026	human	human	MIC	NA	B_STRPT_GRPB	2.5	PEN	Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
1036	1035	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	AMC	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	1	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.
1037	1036	EUCAST 2026	human	human	DISK	indications other than endocarditis and meningitis	B_STRPT_PNMN	2	AMP	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	22	19	FALSE	FALSE	NA
1038	1037	EUCAST 2026	human	human	MIC	indications other than endocarditis and meningitis	B_STRPT_PNMN	2	AMP	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	1	FALSE	FALSE	NA
1039	1038	EUCAST 2026	human	human	MIC	endocarditis and meningitis	B_STRPT_PNMN	2	AMP	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
1040	1039	EUCAST 2026	human	human	MIC	endocarditis and meningitis	B_STRPT_PNMN	2	AMX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
1041	1040	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	AMX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	1	FALSE	FALSE	NA
1042	1041	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	AZM	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1043	1042	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	BPR	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1044	1043	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	CEC	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	50	28	FALSE	FALSE	NA
1045	1044	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	CEC	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	0.5	FALSE	FALSE	NA
1046	1045	EUCAST 2026	human	human	DISK	Topical	B_STRPT_PNMN	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	21	21	FALSE	FALSE	NA
1047	1046	EUCAST 2026	human	human	MIC	Topical	B_STRPT_PNMN	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
1048	1047	EUCAST 2026	human	human	MIC	Topical	B_STRPT_PNMN	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
1049	1048	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	CLI	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	19	19	FALSE	FALSE	[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.
1050	1049	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	CLI	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.
1051	1050	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	CLR	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1052	1051	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	CPD	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1053	1052	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	CPT	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1054	1053	EUCAST 2026	human	human	MIC	indications other than endocarditis and meningitis	B_STRPT_PNMN	2	CRO	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	2	FALSE	FALSE	NA
1055	1054	EUCAST 2026	human	human	MIC	endocarditis and meningitis	B_STRPT_PNMN	2	CRO	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1056	1055	EUCAST 2026	human	human	MIC	indications other than endocarditis and meningitis	B_STRPT_PNMN	2	CTX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	2	FALSE	FALSE	NA
1057	1056	EUCAST 2026	human	human	MIC	endocarditis and meningitis	B_STRPT_PNMN	2	CTX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1058	1057	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	CXM	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	1	FALSE	FALSE	NA
1059	1058	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	CXM	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1060	1059	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	DOR	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
1061	1060	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	DOX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1062	1061	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	ERY	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	22	22	FALSE	FALSE	[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1063	1062	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	ERY	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1064	1063	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	ETP	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1065	1064	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	FEP	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	NA
1066	1065	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	IPM	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1067	1066	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	LMU	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	12	12	FALSE	FALSE	NA
1068	1067	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	LMU	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1069	1068	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	LNZ	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	22	FALSE	FALSE	NA
1070	1069	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	LNZ	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1071	1070	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	LVX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	50	16	FALSE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1072	1071	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	LVX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	2	FALSE	FALSE	NA
1073	1072	EUCAST 2026	human	human	MIC	Topical	B_STRPT_PNMN	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1074	1073	EUCAST 2026	human	human	MIC	indications other than meningitis	B_STRPT_PNMN	2	MEM	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1075	1074	EUCAST 2026	human	human	MIC	meningitis	B_STRPT_PNMN	2	MEM	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1076	1075	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	MFX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	22	22	FALSE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1077	1076	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	MFX	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1078	1077	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	MNO	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	24	24	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1079	1078	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	MNO	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1080	1079	EUCAST 2026	human	human	DISK	screen only	B_STRPT_PNMN	2	NOR	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	10	10	FALSE	FALSE	[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as "susceptible increased exposure" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
1081	1080	EUCAST 2026	human	human	DISK	Topical	B_STRPT_PNMN	2	NOR	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	10	10	FALSE	FALSE	[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).
1082	1081	EUCAST 2026	human	human	MIC	Topical	B_STRPT_PNMN	2	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
1083	1082	EUCAST 2026	human	human	DISK	screen only	B_STRPT_PNMN	2	OXA	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	1 mcg	20	20	FALSE	FALSE	[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.
1084	1083	EUCAST 2026	human	human	MIC	indications other than endocarditis and meningitis	B_STRPT_PNMN	2	PEN	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	1	FALSE	FALSE	NA
1085	1084	EUCAST 2026	human	human	MIC	endocarditis and meningitis	B_STRPT_PNMN	2	PEN	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.06	0.06	FALSE	FALSE	NA
1086	1085	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	RIF	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	22	22	FALSE	FALSE	NA
1087	1086	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	RIF	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
1088	1087	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	RXT	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1089	1088	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	SXT	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	15	15	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1090	1089	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	SXT	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1091	1090	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	TCY	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	25	25	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1092	1091	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	TCY	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1093	1092	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	TEC	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	17	17	FALSE	FALSE	[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1094	1093	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	TEC	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1095	1094	EUCAST 2026	human	human	DISK	NA	B_STRPT_PNMN	2	VAN	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	16	16	FALSE	FALSE	[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1096	1095	EUCAST 2026	human	human	MIC	NA	B_STRPT_PNMN	2	VAN	S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1097	1096	EUCAST 2026	human	human	DISK	indications other than endocarditis	B_STRPT_VIRI	2.5	AMP	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	21	15	FALSE	FALSE	NA
1098	1097	EUCAST 2026	human	human	DISK	endocarditis	B_STRPT_VIRI	2.5	AMP	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	21	21	FALSE	FALSE	NA
1099	1098	EUCAST 2026	human	human	MIC	indications other than endocarditis	B_STRPT_VIRI	2.5	AMP	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	2	FALSE	FALSE	NA
1100	1099	EUCAST 2026	human	human	MIC	endocarditis	B_STRPT_VIRI	2.5	AMP	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1101	1100	EUCAST 2026	human	human	MIC	indications other than endocarditis	B_STRPT_VIRI	2.5	AMX	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	2	FALSE	FALSE	NA
1102	1101	EUCAST 2026	human	human	MIC	endocarditis	B_STRPT_VIRI	2.5	AMX	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1103	1102	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	CLI	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	2 mcg	19	19	FALSE	FALSE	[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.
1104	1103	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	CLI	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.
1105	1104	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	CRO	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	27	FALSE	FALSE	[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.
1106	1105	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	CRO	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1107	1106	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	CTX	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	23	FALSE	FALSE	[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.
1108	1107	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	CTX	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1109	1108	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	CXM	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	26	26	FALSE	FALSE	[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.
1110	1109	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	CXM	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1111	1110	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	DOR	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
1112	1111	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	ERV	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	20 mcg	17	17	FALSE	FALSE	NA
1113	1112	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	ERV	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
1114	1113	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	ETP	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1115	1114	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	FEP	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	25	25	FALSE	FALSE	[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.
1116	1115	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	FEP	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1117	1116	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	IMR	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.
1118	1117	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	IPM	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1119	1118	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	MEM	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1120	1119	EUCAST 2026	human	human	DISK	screen only	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	1 unit	21	21	FALSE	FALSE	[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
1121	1120	EUCAST 2026	human	human	DISK	indications other than endocarditis	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	1 unit	21	12	FALSE	FALSE	NA
1122	1121	EUCAST 2026	human	human	DISK	endocarditis	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	1 unit	21	21	FALSE	FALSE	NA
1123	1122	EUCAST 2026	human	human	DISK	endocarditis, in combination with other antimicrobial treatment	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	1 unit	12	12	FALSE	FALSE	[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1124	1123	EUCAST 2026	human	human	MIC	screen only	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
1125	1124	EUCAST 2026	human	human	MIC	indications other than endocarditis	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	1	FALSE	FALSE	NA
1126	1125	EUCAST 2026	human	human	MIC	endocarditis	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1127	1126	EUCAST 2026	human	human	MIC	endocarditis, in combination with other antimicrobial treatment	B_STRPT_VIRI	2.5	PEN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1128	1127	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	TEC	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	16	16	FALSE	FALSE	[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1129	1128	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	TEC	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1130	1129	EUCAST 2026	human	human	DISK	NA	B_STRPT_VIRI	2.5	VAN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	15	15	FALSE	FALSE	[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1131	1130	EUCAST 2026	human	human	MIC	NA	B_STRPT_VIRI	2.5	VAN	Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1132	1131	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	AZM	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	16	16	FALSE	FALSE	[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.
1133	1132	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	AZM	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	NA
1134	1133	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	CAZ	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	22	FALSE	FALSE	NA
1135	1134	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	CAZ	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
1136	1135	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	CIP	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	23	FALSE	FALSE	[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.
1137	1136	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	CIP	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1138	1137	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	CTX	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	21	21	FALSE	FALSE	NA
1139	1138	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	CTX	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1140	1139	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	DOX	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1141	1140	EUCAST 2026	human	human	DISK	screen only	B_VIBRI	3	ERY	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	15 mcg	12	12	FALSE	FALSE	[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.
1142	1141	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	LVX	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	23	FALSE	FALSE	[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.
1143	1142	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	LVX	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1144	1143	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	MEM	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	FALSE	FALSE	NA
1145	1144	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	MEM	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1146	1145	EUCAST 2026	human	human	DISK	screen only	B_VIBRI	3	PEF	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	22	22	FALSE	FALSE	[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.
1147	1146	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	SXT	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	21	21	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1148	1147	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	SXT	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1149	1148	EUCAST 2026	human	human	DISK	screen only	B_VIBRI	3	TCY	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	20	20	FALSE	FALSE	[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.
1150	1149	EUCAST 2026	human	human	DISK	NA	B_VIBRI	3	TZP	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	26	26	FALSE	FALSE	NA
1151	1150	EUCAST 2026	human	human	MIC	NA	B_VIBRI	3	TZP	Vibrio (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
1152	1151	EUCAST 2026	human	human	DISK	NA	B_[FAM]_MORGNLLC	4	IPM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	50	19	FALSE	FALSE	[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.
1153	1152	EUCAST 2026	human	human	MIC	NA	B_[FAM]_MORGNLLC	4	IPM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	4	FALSE	FALSE	[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.
1154	1153	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	20/10 mcg	19	19	FALSE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1155	1154	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	20/10 mcg	50	19	FALSE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1156	1155	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	20/10 mcg	16	16	TRUE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1157	1156	EUCAST 2026	human	human	DISK	other indications	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	20/10 mcg	50	19	FALSE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1158	1157	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1159	1158	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1160	1159	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	32	32	TRUE	FALSE	[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1161	1160	EUCAST 2026	human	human	MIC	other indications	B_[ORD]_ENTRBCTR	5	AMC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1162	1161	EUCAST 2026	human	human	DISK	systemic infections	B_[ORD]_ENTRBCTR	5	AMK	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	18	18	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1163	1162	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	AMK	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	18	18	FALSE	FALSE	NA
1164	1163	EUCAST 2026	human	human	MIC	systemic infections	B_[ORD]_ENTRBCTR	5	AMK	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1165	1164	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	AMK	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
1166	1165	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	AMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	14	14	FALSE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1167	1166	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	AMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	14	14	TRUE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1168	1167	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	AMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1169	1168	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	AMP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1170	1169	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	AMX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1171	1170	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	AMX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1172	1171	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	AMX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1173	1172	EUCAST 2026	human	human	MIC	other indications	B_[ORD]_ENTRBCTR	5	AMX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.001	8	FALSE	FALSE	[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1174	1173	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	ATM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	26	21	FALSE	FALSE	[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.
1175	1174	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	ATM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	4	FALSE	FALSE	[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.
1176	1175	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	AZA	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30/20 mcg	25	25	FALSE	FALSE	NA
1177	1176	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	AZA	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.
1178	1177	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	BPR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	23	FALSE	FALSE	NA
1179	1178	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	BPR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1180	1179	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	CAZ	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	19	FALSE	FALSE	NA
1181	1180	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	CAZ	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	4	FALSE	FALSE	NA
1182	1181	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	CFM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	17	17	TRUE	FALSE	NA
1183	1182	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	CFM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	TRUE	FALSE	NA
1184	1183	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	CFR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	12	12	TRUE	FALSE	NA
1185	1184	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	CFR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	TRUE	FALSE	NA
1186	1185	EUCAST 2026	human	human	DISK	Topical	B_[ORD]_ENTRBCTR	5	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	17	17	FALSE	FALSE	NA
1187	1186	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	CHL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	FALSE	FALSE	NA
1188	1187	EUCAST 2026	human	human	DISK	indications other than meningitis	B_[ORD]_ENTRBCTR	5	CIP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	25	22	FALSE	FALSE	NA
1189	1188	EUCAST 2026	human	human	MIC	indications other than meningitis	B_[ORD]_ENTRBCTR	5	CIP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.5	FALSE	FALSE	NA
1190	1189	EUCAST 2026	human	human	MIC	meningitis	B_[ORD]_ENTRBCTR	5	CIP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.
1191	1190	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	CIP	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.125	0.125	FALSE	FALSE	NA
1192	1191	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	COL	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).
1193	1192	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	COL	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1194	1193	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	CPD	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	21	21	TRUE	FALSE	NA
1195	1194	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	CPD	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	TRUE	FALSE	NA
1196	1195	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	CPT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	23	FALSE	FALSE	NA
1197	1196	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	CPT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1198	1197	EUCAST 2026	human	human	DISK	indications other than meningitis	B_[ORD]_ENTRBCTR	5	CRO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	24	FALSE	FALSE	NA
1199	1198	EUCAST 2026	human	human	DISK	meningitis	B_[ORD]_ENTRBCTR	5	CRO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	27	FALSE	FALSE	NA
1200	1199	EUCAST 2026	human	human	MIC	indications other than meningitis	B_[ORD]_ENTRBCTR	5	CRO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	NA
1201	1200	EUCAST 2026	human	human	MIC	meningitis	B_[ORD]_ENTRBCTR	5	CRO	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
1202	1201	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	CTB	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	NA
1203	1202	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	CTB	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
1204	1203	EUCAST 2026	human	human	DISK	indications other than meningitis	B_[ORD]_ENTRBCTR	5	CTX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	17	FALSE	FALSE	NA
1205	1204	EUCAST 2026	human	human	DISK	meningitis	B_[ORD]_ENTRBCTR	5	CTX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	20	20	FALSE	FALSE	NA
1206	1205	EUCAST 2026	human	human	MIC	indications other than meningitis	B_[ORD]_ENTRBCTR	5	CTX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	NA
1207	1206	EUCAST 2026	human	human	MIC	meningitis	B_[ORD]_ENTRBCTR	5	CTX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	1	FALSE	FALSE	NA
1208	1207	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	CZA	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10/4 mcg	13	13	FALSE	FALSE	NA
1209	1208	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	CZA	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.
1210	1209	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	CZT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30/10 mcg	22	22	FALSE	FALSE	[7] See table of dosages for dosing for different indications.
1211	1210	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	CZT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.
1212	1211	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	DOR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	21	FALSE	FALSE	NA
1213	1212	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	DOR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	2	FALSE	FALSE	NA
1214	1213	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	ETP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	23	23	FALSE	FALSE	NA
1215	1214	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	ETP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	NA
1216	1215	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	FDC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	23	23	FALSE	FALSE	NA
1217	1216	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	FDC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.
1218	1217	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	FEP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	27	24	FALSE	FALSE	NA
1219	1218	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	FEP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	1	4	FALSE	FALSE	NA
1220	1219	EUCAST 2026	human	human	DISK	screen only	B_[ORD]_ENTRBCTR	5	FOX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	19	19	FALSE	FALSE	[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.
1221	1220	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	FPE	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30/20 mcg	22	22	FALSE	FALSE	NA
1222	1221	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	FPE	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	4	4	FALSE	FALSE	[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.
1223	1222	EUCAST 2026	human	human	DISK	systemic infections	B_[ORD]_ENTRBCTR	5	GEN	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1224	1223	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	GEN	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	NA
1225	1224	EUCAST 2026	human	human	DISK	Topical	B_[ORD]_ENTRBCTR	5	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	17	17	FALSE	FALSE	NA
1226	1225	EUCAST 2026	human	human	MIC	systemic infections	B_[ORD]_ENTRBCTR	5	GEN	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1227	1226	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	GEN	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1228	1227	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	GEN	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1229	1228	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	IMR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10/25 mcg	22	22	FALSE	FALSE	NA
1230	1229	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	IMR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.
1231	1230	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	IPM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	19	FALSE	FALSE	NA
1232	1231	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	IPM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	4	FALSE	FALSE	NA
1233	1232	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	LEX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	14	14	TRUE	FALSE	NA
1234	1233	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	LEX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	16	16	TRUE	FALSE	NA
1235	1234	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	LVX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	23	19	FALSE	FALSE	NA
1236	1235	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	LVX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	1	FALSE	FALSE	NA
1237	1236	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	LVX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1238	1237	EUCAST 2026	human	human	DISK	indications other than meningitis	B_[ORD]_ENTRBCTR	5	MEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	16	FALSE	FALSE	NA
1239	1238	EUCAST 2026	human	human	DISK	meningitis	B_[ORD]_ENTRBCTR	5	MEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	22	22	FALSE	FALSE	NA
1240	1239	EUCAST 2026	human	human	MIC	indications other than meningitis	B_[ORD]_ENTRBCTR	5	MEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	8	FALSE	FALSE	NA
1241	1240	EUCAST 2026	human	human	MIC	meningitis	B_[ORD]_ENTRBCTR	5	MEM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1242	1241	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	MEV	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	20/10 mcg	20	20	FALSE	FALSE	NA
1243	1242	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	MEV	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.
1244	1243	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	MFX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	22	22	FALSE	FALSE	[3] Fluoroquinolone breakpoints are available for other agents.
1245	1244	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	MFX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	[3] Fluoroquinolone breakpoints are available for other agents.
1246	1245	EUCAST 2026	human	human	DISK	Topical	B_[ORD]_ENTRBCTR	5	NEO	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	12	12	FALSE	FALSE	NA
1247	1246	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	NEO	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
1248	1247	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	NOR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	24	24	TRUE	FALSE	NA
1249	1248	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	NOR	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	TRUE	FALSE	NA
1250	1249	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	OFX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	24	22	FALSE	FALSE	NA
1251	1250	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	OFX	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.5	FALSE	FALSE	NA
1252	1251	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	OFX	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	0.25	0.25	FALSE	FALSE	NA
1253	1252	EUCAST 2026	human	human	DISK	screen only	B_[ORD]_ENTRBCTR	5	PEF	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	24	24	FALSE	FALSE	[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.
1254	1253	EUCAST 2026	human	human	DISK	Topical	B_[ORD]_ENTRBCTR	5	PEF	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	5 mcg	24	24	FALSE	FALSE	[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).
1255	1254	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	PIP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30 mcg	20	20	FALSE	FALSE	NA
1256	1255	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	PIP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	NA
1257	1256	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	SAM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	14	14	FALSE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1258	1257	EUCAST 2026	human	human	DISK	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	SAM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10/10 mcg	14	14	TRUE	FALSE	[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1259	1258	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	SAM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1260	1259	EUCAST 2026	human	human	MIC	uncomplicated UTI only	B_[ORD]_ENTRBCTR	5	SAM	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	TRUE	FALSE	[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.
1261	1260	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	SXT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	1.25/23.75 mcg	15	15	FALSE	FALSE	[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1262	1261	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	SXT	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	0.5	0.5	FALSE	FALSE	[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1263	1262	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	TCC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	75/10 mcg	23	20	FALSE	FALSE	NA
1264	1263	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	TCC	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	16	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1265	1264	EUCAST 2026	human	human	DISK	systemic infections	B_[ORD]_ENTRBCTR	5	TOB	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	16	16	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1266	1265	EUCAST 2026	human	human	DISK	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	TOB	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	16	16	FALSE	FALSE	NA
1267	1266	EUCAST 2026	human	human	DISK	Topical	B_[ORD]_ENTRBCTR	5	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	10 mcg	16	16	FALSE	FALSE	NA
1268	1267	EUCAST 2026	human	human	MIC	systemic infections	B_[ORD]_ENTRBCTR	5	TOB	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1269	1268	EUCAST 2026	human	human	MIC	infections originating from the urinary tract	B_[ORD]_ENTRBCTR	5	TOB	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1270	1269	EUCAST 2026	human	human	MIC	Topical	B_[ORD]_ENTRBCTR	5	TOB	Topical agents (file: Clinical Breakpoint Tables v. 16.1)	NA	2	2	FALSE	FALSE	NA
1271	1270	EUCAST 2026	human	human	DISK	NA	B_[ORD]_ENTRBCTR	5	TZP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	30/6 mcg	20	20	FALSE	FALSE	NA
1272	1271	EUCAST 2026	human	human	MIC	NA	B_[ORD]_ENTRBCTR	5	TZP	Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)	NA	8	8	FALSE	FALSE	[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
1273	1272	EUCAST 2026	human	human	MIC	NA	F_ASPRG_FLAVS	2	ISV	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1274	1273	EUCAST 2026	human	human	MIC	NA	F_ASPRG_FLAVS	2	ITR	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.
1275	1274	EUCAST 2026	human	human	MIC	NA	F_ASPRG_MGTS	2	AMB	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1276	1275	EUCAST 2026	human	human	MIC	NA	F_ASPRG_MGTS	2	ISV	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1277	1276	EUCAST 2026	human	human	MIC	NA	F_ASPRG_MGTS	2	ITR	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.
1278	1277	EUCAST 2026	human	human	MIC	NA	F_ASPRG_MGTS	2	POS	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.125	0.125	FALSE	FALSE	NA
1279	1278	EUCAST 2026	human	human	MIC	NA	F_ASPRG_MGTS	2	VOR	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.
1280	1279	EUCAST 2026	human	human	MIC	NA	F_ASPRG_NDLN	2	ISV	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.5	0.5	FALSE	FALSE	NA
1281	1280	EUCAST 2026	human	human	MIC	NA	F_ASPRG_NDLN	2	ITR	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.
1282	1281	EUCAST 2026	human	human	MIC	NA	F_ASPRG_NDLN	2	VOR	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.
1283	1282	EUCAST 2026	human	human	MIC	NA	F_ASPRG_NIGR	2	AMB	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1284	1283	EUCAST 2026	human	human	MIC	NA	F_ASPRG_TERRS	2	ISV	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1285	1284	EUCAST 2026	human	human	MIC	NA	F_ASPRG_TERRS	2	ITR	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.
1286	1285	EUCAST 2026	human	human	MIC	NA	F_ASPRG_TERRS	2	POS	6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.125	0.125	FALSE	FALSE	NA
1287	1286	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1288	1287	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	ANI	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.016	0.016	FALSE	FALSE	NA
1289	1288	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	FLU	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	2	4	FALSE	FALSE	NA
1290	1289	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	ITR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1291	1290	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	MIF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.03	0.03	FALSE	FALSE	NA
1292	1291	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	POS	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1293	1292	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	RZF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.008	0.008	FALSE	FALSE	[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.
1294	1293	EUCAST 2026	human	human	MIC	NA	F_CANDD_ALBC	2	VOR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.25	FALSE	FALSE	[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.
1295	1294	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1296	1295	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	ANI	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.03	0.03	FALSE	FALSE	NA
1297	1296	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	FLU	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	2	4	FALSE	FALSE	NA
1298	1297	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	ITR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1299	1298	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	MIF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1300	1299	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	POS	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1301	1300	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	RZF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.016	0.016	FALSE	FALSE	[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.
1302	1301	EUCAST 2026	human	human	MIC	NA	F_CANDD_DBLN	2	VOR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.25	FALSE	FALSE	[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.
1303	1302	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1304	1303	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	ANI	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	4	4	FALSE	FALSE	NA
1305	1304	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	FLU	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	2	4	FALSE	FALSE	NA
1306	1305	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	ITR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.125	0.125	FALSE	FALSE	NA
1307	1306	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	MIF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	4	4	FALSE	FALSE	NA
1308	1307	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	POS	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1309	1308	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	RZF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	4	4	FALSE	FALSE	[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.
1310	1309	EUCAST 2026	human	human	MIC	NA	F_CANDD_PRPS	2	VOR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.125	0.25	FALSE	FALSE	NA
1311	1310	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1312	1311	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	ANI	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1313	1312	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	FLU	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	2	4	FALSE	FALSE	NA
1314	1313	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	ITR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.125	0.125	FALSE	FALSE	NA
1315	1314	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	MIF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1316	1315	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	POS	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1317	1316	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	RZF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.03	0.03	FALSE	FALSE	[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.
1318	1317	EUCAST 2026	human	human	MIC	NA	F_CANDD_TRPC	2	VOR	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.125	0.25	FALSE	FALSE	[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.
1319	1318	EUCAST 2026	human	human	MIC	NA	F_CNDDZ_AURS	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.001	2	FALSE	FALSE	[1] The entire C. auris wild-type population is in the I category. The Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any WT strains as "S" strains.
1320	1319	EUCAST 2026	human	human	MIC	NA	F_CNDDZ_AURS	2	ANI	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.25	0.25	FALSE	FALSE	NA
1321	1320	EUCAST 2026	human	human	MIC	NA	F_CNDDZ_AURS	2	MIF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.25	0.25	FALSE	FALSE	NA
1322	1321	EUCAST 2026	human	human	MIC	NA	F_CRYPT_NFRM	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1323	1322	EUCAST 2026	human	human	MIC	NA	F_NKSMY_BRTS	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1324	1323	EUCAST 2026	human	human	MIC	NA	F_NKSMY_BRTS	2	ANI	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1325	1324	EUCAST 2026	human	human	MIC	NA	F_NKSMY_BRTS	2	FLU	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.001	16	FALSE	FALSE	[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as "S" strains.
1326	1325	EUCAST 2026	human	human	MIC	NA	F_NKSMY_BRTS	2	MIF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1327	1326	EUCAST 2026	human	human	MIC	NA	F_NKSMY_BRTS	2	RZF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.016	0.016	FALSE	FALSE	[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.
1328	1327	EUCAST 2026	human	human	MIC	NA	F_PICHI_KDRV	2	AMB	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	1	1	FALSE	FALSE	NA
1329	1328	EUCAST 2026	human	human	MIC	NA	F_PICHI_KDRV	2	ANI	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.06	0.06	FALSE	FALSE	NA
1330	1329	EUCAST 2026	human	human	MIC	NA	F_PICHI_KDRV	2	RZF	5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)	NA	0.03	0.03	FALSE	FALSE	[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.
1331	1330	EUCAST 2025	human	human	DISK	NA	B_ACHRMB_XYLS	2	MEM	A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	26	20	FALSE	FALSE	NA
1332	1331	EUCAST 2025	human	human	MIC	NA	B_ACHRMB_XYLS	2	MEM	A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)	NA	1	4	FALSE	FALSE	NA
1333	1332	EUCAST 2025	human	human	DISK	NA	B_ACHRMB_XYLS	2	SXT	A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	26	26	FALSE	FALSE	[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1334	1333	EUCAST 2025	human	human	MIC	NA	B_ACHRMB_XYLS	2	SXT	A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1335	1334	EUCAST 2025	human	human	DISK	NA	B_ACHRMB_XYLS	2	TZP	A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)	30/6 mcg	26	26	FALSE	FALSE	NA
1336	1335	EUCAST 2025	human	human	MIC	NA	B_ACHRMB_XYLS	2	TZP	A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
1337	1336	EUCAST 2025	human	human	DISK	systemic infections	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	19	19	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1338	1337	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	19	19	FALSE	FALSE	NA
1339	1338	EUCAST 2025	human	human	MIC	systemic infections	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1340	1339	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_ACNTB	3	AMK	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	FALSE	FALSE	NA
1341	1340	EUCAST 2025	human	human	DISK	NA	B_ACNTB	3	CIP	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	21	FALSE	FALSE	NA
1342	1341	EUCAST 2025	human	human	DISK	Topical	B_ACNTB	3	CIP	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	21	21	FALSE	FALSE	NA
1343	1342	EUCAST 2025	human	human	MIC	NA	B_ACNTB	3	CIP	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1344	1343	EUCAST 2025	human	human	MIC	Topical	B_ACNTB	3	CIP	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1345	1344	EUCAST 2025	human	human	MIC	NA	B_ACNTB	3	COL	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).
1346	1345	EUCAST 2025	human	human	MIC	Topical	B_ACNTB	3	COL	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1347	1346	EUCAST 2025	human	human	DISK	NA	B_ACNTB	3	DOR	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	50	22	FALSE	FALSE	NA
1348	1347	EUCAST 2025	human	human	MIC	NA	B_ACNTB	3	DOR	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	2	FALSE	FALSE	NA
1349	1348	EUCAST 2025	human	human	DISK	systemic infections	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1350	1349	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	NA
1351	1350	EUCAST 2025	human	human	DISK	Topical	B_ACNTB	3	GEN	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	NA
1352	1351	EUCAST 2025	human	human	MIC	systemic infections	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1353	1352	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_ACNTB	3	GEN	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1354	1353	EUCAST 2025	human	human	MIC	Topical	B_ACNTB	3	GEN	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1355	1354	EUCAST 2025	human	human	DISK	NA	B_ACNTB	3	IPM	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	24	21	FALSE	FALSE	NA
1356	1355	EUCAST 2025	human	human	MIC	NA	B_ACNTB	3	IPM	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	2	4	FALSE	FALSE	NA
1357	1356	EUCAST 2025	human	human	DISK	NA	B_ACNTB	3	LVX	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	23	20	FALSE	FALSE	NA
1358	1357	EUCAST 2025	human	human	DISK	Topical	B_ACNTB	3	LVX	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	23	23	FALSE	FALSE	NA
1359	1358	EUCAST 2025	human	human	MIC	NA	B_ACNTB	3	LVX	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	1	FALSE	FALSE	NA
1360	1359	EUCAST 2025	human	human	MIC	Topical	B_ACNTB	3	LVX	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1361	1360	EUCAST 2025	human	human	DISK	indications other than meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	21	15	FALSE	FALSE	NA
1362	1361	EUCAST 2025	human	human	DISK	meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	21	21	FALSE	FALSE	NA
1363	1362	EUCAST 2025	human	human	MIC	indications other than meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	2	8	FALSE	FALSE	NA
1364	1363	EUCAST 2025	human	human	MIC	meningitis	B_ACNTB	3	MEM	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1365	1364	EUCAST 2025	human	human	MIC	Topical	B_ACNTB	3	OFX	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1366	1365	EUCAST 2025	human	human	DISK	NA	B_ACNTB	3	SXT	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	14	11	FALSE	FALSE	[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1367	1366	EUCAST 2025	human	human	MIC	NA	B_ACNTB	3	SXT	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	2	4	FALSE	FALSE	[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1368	1367	EUCAST 2025	human	human	DISK	systemic infections	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1369	1368	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	NA
1370	1369	EUCAST 2025	human	human	DISK	Topical	B_ACNTB	3	TOB	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	NA
1371	1370	EUCAST 2025	human	human	MIC	systemic infections	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1372	1371	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_ACNTB	3	TOB	Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1373	1372	EUCAST 2025	human	human	MIC	Topical	B_ACNTB	3	TOB	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1374	1373	EUCAST 2025	human	human	DISK	NA	B_AERCC_SNGN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	26	26	FALSE	FALSE	NA
1375	1374	EUCAST 2025	human	human	MIC	NA	B_AERCC_SNGN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1376	1375	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_AERCC_SNGN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	21	21	TRUE	FALSE	[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note
1377	1376	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_AERCC_SNGN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	TRUE	FALSE	NA
1378	1377	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_AERCC_SNGN	2	LVX	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	TRUE	FALSE	[1] Susceptibility can be inferred from ciprofloxacin susceptibility.
1379	1378	EUCAST 2025	human	human	DISK	NA	B_AERCC_SNGN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	31	31	FALSE	FALSE	NA
1380	1379	EUCAST 2025	human	human	MIC	NA	B_AERCC_SNGN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1381	1380	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_AERCC_SNGN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	100 mcg	16	16	TRUE	FALSE	NA
1382	1381	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_AERCC_SNGN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	16	16	TRUE	FALSE	NA
1383	1382	EUCAST 2025	human	human	DISK	screen only	B_AERCC_SNGN	2	NOR	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.
1384	1383	EUCAST 2025	human	human	DISK	NA	B_AERCC_SNGN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	1 unit	21	21	FALSE	FALSE	NA
1385	1384	EUCAST 2025	human	human	MIC	NA	B_AERCC_SNGN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1386	1385	EUCAST 2025	human	human	DISK	NA	B_AERCC_SNGN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	25	25	FALSE	FALSE	NA
1387	1386	EUCAST 2025	human	human	MIC	NA	B_AERCC_SNGN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1388	1387	EUCAST 2025	human	human	DISK	NA	B_AERCC_SNGN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	16	16	FALSE	FALSE	[A] Non-wild type isolates were not available when developing the disk diffusion method.
1389	1388	EUCAST 2025	human	human	MIC	NA	B_AERCC_SNGN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1390	1389	EUCAST 2025	human	human	DISK	NA	B_AERCC_URIN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	26	26	FALSE	FALSE	NA
1391	1390	EUCAST 2025	human	human	MIC	NA	B_AERCC_URIN	2	AMP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1392	1391	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_AERCC_URIN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	21	21	TRUE	FALSE	[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note
1393	1392	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_AERCC_URIN	2	CIP	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	TRUE	FALSE	NA
1394	1393	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_AERCC_URIN	2	LVX	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	TRUE	FALSE	[1] Susceptibility can be inferred from ciprofloxacin susceptibility.
1395	1394	EUCAST 2025	human	human	DISK	NA	B_AERCC_URIN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	31	31	FALSE	FALSE	NA
1396	1395	EUCAST 2025	human	human	MIC	NA	B_AERCC_URIN	2	MEM	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1397	1396	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_AERCC_URIN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	100 mcg	16	16	TRUE	FALSE	NA
1398	1397	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_AERCC_URIN	2	NIT	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	16	16	TRUE	FALSE	NA
1399	1398	EUCAST 2025	human	human	DISK	screen only	B_AERCC_URIN	2	NOR	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	17	17	FALSE	FALSE	[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.
1400	1399	EUCAST 2025	human	human	DISK	NA	B_AERCC_URIN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	1 unit	21	21	FALSE	FALSE	NA
1401	1400	EUCAST 2025	human	human	MIC	NA	B_AERCC_URIN	2	PEN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1402	1401	EUCAST 2025	human	human	DISK	NA	B_AERCC_URIN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	25	25	FALSE	FALSE	NA
1403	1402	EUCAST 2025	human	human	MIC	NA	B_AERCC_URIN	2	RIF	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1404	1403	EUCAST 2025	human	human	DISK	NA	B_AERCC_URIN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	16	16	FALSE	FALSE	[A] Non-wild type isolates were not available when developing the disk diffusion method.
1405	1404	EUCAST 2025	human	human	MIC	NA	B_AERCC_URIN	2	VAN	A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1406	1405	EUCAST 2025	human	human	DISK	NA	B_AERMN	3	ATM	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	29	26	FALSE	FALSE	NA
1407	1406	EUCAST 2025	human	human	MIC	NA	B_AERMN	3	ATM	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	NA	1	4	FALSE	FALSE	NA
1408	1407	EUCAST 2025	human	human	DISK	NA	B_AERMN	3	CAZ	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	24	21	FALSE	FALSE	NA
1409	1408	EUCAST 2025	human	human	MIC	NA	B_AERMN	3	CAZ	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	NA	1	4	FALSE	FALSE	NA
1410	1409	EUCAST 2025	human	human	DISK	NA	B_AERMN	3	CIP	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	27	24	FALSE	FALSE	NA
1411	1410	EUCAST 2025	human	human	MIC	NA	B_AERMN	3	CIP	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.5	FALSE	FALSE	NA
1412	1411	EUCAST 2025	human	human	DISK	NA	B_AERMN	3	FEP	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	27	24	FALSE	FALSE	NA
1413	1412	EUCAST 2025	human	human	MIC	NA	B_AERMN	3	FEP	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	NA	1	4	FALSE	FALSE	NA
1414	1413	EUCAST 2025	human	human	DISK	NA	B_AERMN	3	LVX	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	27	24	FALSE	FALSE	NA
1415	1414	EUCAST 2025	human	human	MIC	NA	B_AERMN	3	LVX	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	1	FALSE	FALSE	NA
1416	1415	EUCAST 2025	human	human	DISK	NA	B_AERMN	3	SXT	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	19	16	FALSE	FALSE	[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1417	1416	EUCAST 2025	human	human	MIC	NA	B_AERMN	3	SXT	Aeromonas (file: Clinical Breakpoint Tables v. 15.0)	NA	2	4	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1418	1417	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	CIP	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	23	FALSE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1419	1418	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	CIP	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.5	FALSE	FALSE	NA
1420	1419	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	CLI	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	17	17	FALSE	FALSE	NA
1421	1420	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	CLI	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1422	1421	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	ERY	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	24	24	FALSE	FALSE	NA
1423	1422	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	ERY	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1424	1423	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	IPM	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	30	30	FALSE	FALSE	NA
1425	1424	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	IPM	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1426	1425	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	LNZ	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	22	22	FALSE	FALSE	NA
1427	1426	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	LNZ	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1428	1427	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	LVX	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	23	FALSE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1429	1428	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	LVX	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1430	1429	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	MEM	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	25	25	FALSE	FALSE	NA
1431	1430	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	MEM	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1432	1431	EUCAST 2025	human	human	DISK	screen only	B_BCLLS	3	NOR	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	21	21	FALSE	FALSE	[B] | [B] Isolates categorised as screen negative can be reported "susceptible increased exposure" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.
1433	1432	EUCAST 2025	human	human	DISK	NA	B_BCLLS	3	VAN	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	10	10	FALSE	FALSE	[A] Non-wild type isolates were not available when developing the disk diffusion method.
1434	1433	EUCAST 2025	human	human	MIC	NA	B_BCLLS	3	VAN	Bacillus (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1435	1434	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	AMX	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.
1436	1435	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	CIP	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	24	FALSE	FALSE	NA
1437	1436	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	CIP	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.25	FALSE	FALSE	NA
1438	1437	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	CLI	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	17	17	FALSE	FALSE	NA
1439	1438	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	CLI	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1440	1439	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	DOX	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
1441	1440	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	LNZ	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	20	20	FALSE	FALSE	NA
1442	1441	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	LNZ	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1443	1442	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	LVX	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	23	FALSE	FALSE	NA
1444	1443	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	LVX	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.5	FALSE	FALSE	NA
1445	1444	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	PEN	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	1 unit	50	18	FALSE	FALSE	NA
1446	1445	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	PEN	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.5	FALSE	FALSE	NA
1447	1446	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	RIF	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	12	12	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1448	1447	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	RIF	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1449	1448	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	TCY	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	26	26	FALSE	FALSE	NA
1450	1449	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	TCY	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1451	1450	EUCAST 2025	human	human	DISK	NA	B_BCLLS_ANTH	2	VAN	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	10	10	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1452	1451	EUCAST 2025	human	human	MIC	NA	B_BCLLS_ANTH	2	VAN	B.anthracis (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1453	1452	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	AMC	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	14	14	FALSE	FALSE	NA
1454	1453	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	AMC	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1455	1454	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	10	10	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
1456	1455	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1457	1456	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	23	23	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1458	1457	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1459	1458	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	29	29	FALSE	FALSE	NA
1460	1459	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1461	1460	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	28	28	FALSE	FALSE	NA
1462	1461	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1463	1462	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	MTR	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	25	25	FALSE	FALSE	NA
1464	1463	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	MTR	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1465	1464	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	SAM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10/10 mcg	25	25	FALSE	FALSE	NA
1466	1465	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	SAM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
1467	1466	EUCAST 2025	human	human	DISK	NA	B_BCTRD	3	TZP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	30/6 mcg	24	24	FALSE	FALSE	[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.
1468	1467	EUCAST 2025	human	human	MIC	NA	B_BCTRD	3	TZP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.
1469	1468	EUCAST 2025	human	human	DISK	NA	B_BRCLL_MLTN	2	CIP	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	27	FALSE	FALSE	NA
1470	1469	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	CIP	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1471	1470	EUCAST 2025	human	human	DISK	meningitis	B_BRCLL_MLTN	2	CRO	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	30	30	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1472	1471	EUCAST 2025	human	human	MIC	meningitis	B_BRCLL_MLTN	2	CRO	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1473	1472	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	DOX	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
1474	1473	EUCAST 2025	human	human	DISK	NA	B_BRCLL_MLTN	2	GEN	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	23	23	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1475	1474	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	GEN	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1476	1475	EUCAST 2025	human	human	DISK	NA	B_BRCLL_MLTN	2	LVX	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	28	FALSE	FALSE	NA
1477	1476	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	LVX	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1478	1477	EUCAST 2025	human	human	DISK	NA	B_BRCLL_MLTN	2	RIF	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	20	20	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.
1479	1478	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	RIF	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1480	1479	EUCAST 2025	human	human	DISK	NA	B_BRCLL_MLTN	2	STR1	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	15	15	FALSE	FALSE	[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1481	1480	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	STR1	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1482	1481	EUCAST 2025	human	human	DISK	NA	B_BRCLL_MLTN	2	SXT	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	29	29	FALSE	FALSE	[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1483	1482	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	SXT	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1484	1483	EUCAST 2025	human	human	DISK	NA	B_BRCLL_MLTN	2	TCY	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	42	42	FALSE	FALSE	NA
1485	1484	EUCAST 2025	human	human	MIC	NA	B_BRCLL_MLTN	2	TCY	B.melitensis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1486	1485	EUCAST 2025	human	human	DISK	NA	B_BRKHL_PSDM	2	AMC	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	20/10 mcg	50	22	FALSE	FALSE	NA
1487	1486	EUCAST 2025	human	human	MIC	NA	B_BRKHL_PSDM	2	AMC	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	8	FALSE	FALSE	[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1488	1487	EUCAST 2025	human	human	DISK	NA	B_BRKHL_PSDM	2	CAZ	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	50	18	FALSE	FALSE	NA
1489	1488	EUCAST 2025	human	human	MIC	NA	B_BRKHL_PSDM	2	CAZ	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	8	FALSE	FALSE	NA
1490	1489	EUCAST 2025	human	human	DISK	NA	B_BRKHL_PSDM	2	CHL	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	22	FALSE	FALSE	NA
1491	1490	EUCAST 2025	human	human	MIC	NA	B_BRKHL_PSDM	2	CHL	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	8	FALSE	FALSE	NA
1492	1491	EUCAST 2025	human	human	MIC	NA	B_BRKHL_PSDM	2	DOX	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	2	FALSE	FALSE	NA
1493	1492	EUCAST 2025	human	human	DISK	NA	B_BRKHL_PSDM	2	IPM	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	29	29	FALSE	FALSE	NA
1494	1493	EUCAST 2025	human	human	MIC	NA	B_BRKHL_PSDM	2	IPM	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1495	1494	EUCAST 2025	human	human	DISK	NA	B_BRKHL_PSDM	2	MEM	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	24	24	FALSE	FALSE	NA
1496	1495	EUCAST 2025	human	human	MIC	NA	B_BRKHL_PSDM	2	MEM	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1497	1496	EUCAST 2025	human	human	DISK	NA	B_BRKHL_PSDM	2	SXT	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	50	17	FALSE	FALSE	[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1498	1497	EUCAST 2025	human	human	MIC	NA	B_BRKHL_PSDM	2	SXT	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	4	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1499	1498	EUCAST 2025	human	human	DISK	screen only	B_BRKHL_PSDM	2	TCY	B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	23	23	FALSE	FALSE	[A] Isolates categorised as screen negative can be reported "susceptible increased exposure" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.
1500	1499	EUCAST 2025	human	human	DISK	NA	B_CMPYL_COLI	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	26	FALSE	FALSE	NA
1501	1500	EUCAST 2025	human	human	MIC	NA	B_CMPYL_COLI	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.5	FALSE	FALSE	NA
1502	1501	EUCAST 2025	human	human	DISK	NA	B_CMPYL_COLI	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	24	24	FALSE	FALSE	[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
1503	1502	EUCAST 2025	human	human	MIC	NA	B_CMPYL_COLI	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	FALSE	FALSE	[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
1504	1503	EUCAST 2025	human	human	DISK	NA	B_CMPYL_COLI	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	30	30	FALSE	FALSE	[A] Susceptibility to doxycycline can be inferred from tetracycline.
1505	1504	EUCAST 2025	human	human	MIC	NA	B_CMPYL_COLI	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] Susceptibility to doxycycline can be inferred from tetracycline.
1506	1505	EUCAST 2025	human	human	DISK	NA	B_CMPYL_JEJN	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	26	FALSE	FALSE	NA
1507	1506	EUCAST 2025	human	human	MIC	NA	B_CMPYL_JEJN	2	CIP	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.5	FALSE	FALSE	NA
1508	1507	EUCAST 2025	human	human	DISK	NA	B_CMPYL_JEJN	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	20	20	FALSE	FALSE	[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
1509	1508	EUCAST 2025	human	human	MIC	NA	B_CMPYL_JEJN	2	ERY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.
1510	1509	EUCAST 2025	human	human	DISK	NA	B_CMPYL_JEJN	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	30	30	FALSE	FALSE	[A] Susceptibility to doxycycline can be inferred from tetracycline.
1511	1510	EUCAST 2025	human	human	MIC	NA	B_CMPYL_JEJN	2	TCY	C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] Susceptibility to doxycycline can be inferred from tetracycline.
1512	1511	EUCAST 2025	human	human	MIC	NA	B_CRDDS_DFFC	2	FDX	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.
1513	1512	EUCAST 2025	human	human	MIC	NA	B_CRDDS_DFFC	2	MTR	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.
1514	1513	EUCAST 2025	human	human	MIC	NA	B_CRDDS_DFFC	2	VAN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.
1515	1514	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	CIP	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	25	FALSE	FALSE	NA
1516	1515	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	CIP	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1517	1516	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	CLI	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	20	20	FALSE	FALSE	[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.
1518	1517	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	CLI	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.
1519	1518	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	LNZ	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	25	25	FALSE	FALSE	NA
1520	1519	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	LNZ	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1521	1520	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	MFX	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	25	25	FALSE	FALSE	NA
1522	1521	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	MFX	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1523	1522	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	PEN	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	1 unit	50	12	FALSE	FALSE	NA
1524	1523	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	PEN	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1525	1524	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	RIF	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	30	30	FALSE	FALSE	NA
1526	1525	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	RIF	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1527	1526	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	TCY	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	24	24	FALSE	FALSE	NA
1528	1527	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	TCY	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1529	1528	EUCAST 2025	human	human	DISK	NA	B_CRYNB	3	VAN	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	17	17	FALSE	FALSE	[A] Non-wild typeisolates were not available when developing the disk diffusion method.
1530	1529	EUCAST 2025	human	human	MIC	NA	B_CRYNB	3	VAN	Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1531	1530	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	AMX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.
1532	1531	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	24	FALSE	FALSE	NA
1533	1532	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.5	FALSE	FALSE	NA
1534	1533	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	CLI	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	15	15	FALSE	FALSE	[1] Wild-type C. ulcerans is less susceptible to clindamycin.
1535	1534	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	CLI	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Wild-type C. ulcerans is less susceptible to clindamycin.
1536	1535	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	15	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
1537	1536	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	2	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
1538	1537	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	DOX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
1539	1538	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	24	24	FALSE	FALSE	NA
1540	1539	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1541	1540	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	25	25	FALSE	FALSE	NA
1542	1541	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1543	1542	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	24	24	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
1544	1543	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
1545	1544	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	1 unit	50	12	FALSE	FALSE	NA
1546	1545	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1547	1546	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	24	24	FALSE	FALSE	NA
1548	1547	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1549	1548	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	23	23	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1550	1549	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1551	1550	EUCAST 2025	human	human	DISK	NA	B_CRYNB_DPHT	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	24	24	FALSE	FALSE	NA
1552	1551	EUCAST 2025	human	human	MIC	NA	B_CRYNB_DPHT	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1553	1552	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	AMX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.
1554	1553	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	24	FALSE	FALSE	NA
1555	1554	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	CIP	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	0.5	FALSE	FALSE	NA
1556	1555	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	50	15	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
1557	1556	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	CTX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	2	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported "susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.
1558	1557	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	DOX	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.
1559	1558	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	24	24	FALSE	FALSE	NA
1560	1559	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	ERY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1561	1560	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	25	25	FALSE	FALSE	NA
1562	1561	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	LNZ	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1563	1562	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	24	24	FALSE	FALSE	[A] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
1564	1563	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	MEM	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates "susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.
1565	1564	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	1 unit	50	12	FALSE	FALSE	NA
1566	1565	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	PEN	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1567	1566	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	24	24	FALSE	FALSE	NA
1568	1567	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	RIF	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1569	1568	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	23	23	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1570	1569	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	SXT	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1571	1570	EUCAST 2025	human	human	DISK	NA	B_CRYNB_ULCR	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	24	24	FALSE	FALSE	NA
1572	1571	EUCAST 2025	human	human	MIC	NA	B_CRYNB_ULCR	2	TCY	C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1573	1572	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	AMC	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1574	1573	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	AMP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1575	1574	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	AMP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1576	1575	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	AMX	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1577	1576	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	26	26	FALSE	FALSE	[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
1578	1577	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1579	1578	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	CRO	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
1580	1579	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	CRO	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1581	1580	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	CTX	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	26	26	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.
1582	1581	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1583	1582	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1584	1583	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	39	39	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1585	1584	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.03	0.03	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1586	1585	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	LNZ	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	34	34	FALSE	FALSE	NA
1587	1586	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	LNZ	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1588	1587	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	28	28	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1589	1588	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1590	1589	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	PEN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	1 unit	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1591	1590	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	PEN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1592	1591	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	SAM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10/10 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1593	1592	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	TZP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	30/6 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1594	1593	EUCAST 2025	human	human	DISK	NA	B_CTBCTR_ACNS	2	VAN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	22	22	FALSE	FALSE	NA
1595	1594	EUCAST 2025	human	human	MIC	NA	B_CTBCTR_ACNS	2	VAN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1596	1595	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_CTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
1597	1596	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_CTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
1598	1597	EUCAST 2025	human	human	DISK	NA	B_CTRBC_KOSR	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	18	18	FALSE	FALSE	[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.
1599	1598	EUCAST 2025	human	human	MIC	NA	B_CTRBC_KOSR	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.
1600	1599	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	AMC	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1601	1600	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	AMC	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1602	1601	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	AMP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1603	1602	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	AMP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1604	1603	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	AMX	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1605	1604	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	19	19	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
1606	1605	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1607	1606	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1608	1607	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1609	1608	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1610	1609	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1611	1610	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1612	1611	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1613	1612	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	MTR	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	16	16	FALSE	FALSE	NA
1614	1613	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	MTR	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1615	1614	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	PEN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	1 unit	15	15	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1616	1615	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	PEN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1617	1616	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	SAM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10/10 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1618	1617	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	SAM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
1619	1618	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	TZP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	30/6 mcg	24	24	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1620	1619	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	TZP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
1621	1620	EUCAST 2025	human	human	DISK	NA	B_CTRDM_PRFR	2	VAN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	12	12	FALSE	FALSE	NA
1622	1621	EUCAST 2025	human	human	MIC	NA	B_CTRDM_PRFR	2	VAN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1623	1622	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ENTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
1624	1623	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ENTRBC	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
1625	1624	EUCAST 2025	human	human	DISK	NA	B_ENTRC	3	AMP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	10	10	FALSE	FALSE	[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.
1626	1625	EUCAST 2025	human	human	MIC	NA	B_ENTRC	3	AMP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1627	1626	EUCAST 2025	human	human	MIC	NA	B_ENTRC	3	AMX	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	[1] Susceptibility can be inferred from ampicillin.
1628	1627	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ENTRC	3	AMX	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	TRUE	FALSE	[1] Susceptibility can be inferred from ampicillin.
1629	1628	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ENTRC	3	CIP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	15	15	TRUE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1630	1629	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ENTRC	3	CIP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	TRUE	FALSE	NA
1631	1630	EUCAST 2025	human	human	DISK	NA	B_ENTRC	3	ERV	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	20 mcg	22	22	FALSE	FALSE	NA
1632	1631	EUCAST 2025	human	human	MIC	NA	B_ENTRC	3	ERV	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1633	1632	EUCAST 2025	human	human	DISK	NA	B_ENTRC	3	LNZ	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	20	20	FALSE	FALSE	NA
1634	1633	EUCAST 2025	human	human	MIC	NA	B_ENTRC	3	LNZ	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1635	1634	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ENTRC	3	LVX	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	15	15	TRUE	FALSE	[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1636	1635	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ENTRC	3	LVX	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	TRUE	FALSE	NA
1637	1636	EUCAST 2025	human	human	DISK	screen only	B_ENTRC	3	NOR	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	12	12	FALSE	FALSE	[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.
1638	1637	EUCAST 2025	human	human	DISK	NA	B_ENTRC	3	TEC	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	16	16	FALSE	FALSE	NA
1639	1638	EUCAST 2025	human	human	MIC	NA	B_ENTRC	3	TEC	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1640	1639	EUCAST 2025	human	human	DISK	NA	B_ENTRC	3	TGC	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	20	20	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1641	1640	EUCAST 2025	human	human	MIC	NA	B_ENTRC	3	TGC	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1642	1641	EUCAST 2025	human	human	DISK	NA	B_ENTRC	3	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	15	15	FALSE	FALSE	NA
1643	1642	EUCAST 2025	human	human	MIC	NA	B_ENTRC	3	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1644	1643	EUCAST 2025	human	human	DISK	NA	B_ENTRC_FACM	2	QDA	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	22	22	FALSE	FALSE	NA
1645	1644	EUCAST 2025	human	human	MIC	NA	B_ENTRC_FACM	2	QDA	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1646	1645	EUCAST 2025	human	human	DISK	NA	B_ENTRC_FACM	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	12	12	FALSE	FALSE	[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.
1647	1646	EUCAST 2025	human	human	MIC	NA	B_ENTRC_FACM	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1648	1647	EUCAST 2025	human	human	MIC	other indications	B_ENTRC_FCLS	2	AMX	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	4	FALSE	FALSE	[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.
1649	1648	EUCAST 2025	human	human	DISK	NA	B_ENTRC_FCLS	2	IPM	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	50	21	FALSE	FALSE	NA
1650	1649	EUCAST 2025	human	human	MIC	NA	B_ENTRC_FCLS	2	IPM	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	4	FALSE	FALSE	NA
1651	1650	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ENTRC_FCLS	2	NIT	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	100 mcg	15	15	TRUE	FALSE	NA
1652	1651	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ENTRC_FCLS	2	NIT	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	64	64	TRUE	FALSE	NA
1653	1652	EUCAST 2025	human	human	DISK	NA	B_ENTRC_FCLS	2	PIP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	18	FALSE	FALSE	NA
1654	1653	EUCAST 2025	human	human	MIC	NA	B_ENTRC_FCLS	2	PIP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	16	FALSE	FALSE	NA
1655	1654	EUCAST 2025	human	human	DISK	NA	B_ENTRC_FCLS	2	TZP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	30/6 mcg	50	18	FALSE	FALSE	[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.
1656	1655	EUCAST 2025	human	human	MIC	NA	B_ENTRC_FCLS	2	TZP	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	16	FALSE	FALSE	[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.
1657	1656	EUCAST 2025	human	human	DISK	NA	B_ENTRC_FCLS	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	12	12	FALSE	FALSE	[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.
1658	1657	EUCAST 2025	human	human	MIC	NA	B_ENTRC_FCLS	2	VAN	Enterococcus (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1659	1658	EUCAST 2025	human	human	DISK	NA	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	19	FALSE	FALSE	NA
1660	1659	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	19	19	TRUE	FALSE	NA
1661	1660	EUCAST 2025	human	human	MIC	NA	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	8	FALSE	FALSE	NA
1662	1661	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	TRUE	FALSE	NA
1663	1662	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_ESCHR_COLI	2	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	20	FALSE	FALSE	[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
1664	1663	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_ESCHR_COLI	2	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	4	FALSE	FALSE	[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
1665	1664	EUCAST 2025	human	human	MIC	NA	B_ESCHR_COLI	2	DFX	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1666	1665	EUCAST 2025	human	human	DISK	NA	B_ESCHR_COLI	2	ERV	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	20 mcg	17	17	FALSE	FALSE	NA
1667	1666	EUCAST 2025	human	human	MIC	NA	B_ESCHR_COLI	2	ERV	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1668	1667	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	200 mcg	24	24	FALSE	FALSE	[D] Ignore isolated colonies within the inhibition zone (see pictures below).
1669	1668	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	200 mcg	24	24	TRUE	FALSE	[D] Ignore isolated colonies within the inhibition zone (see pictures below).
1670	1669	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	FALSE	FALSE	[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.
1671	1670	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	FOS	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	TRUE	FALSE	[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.
1672	1671	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
1673	1672	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
1674	1673	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	NIT	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	100 mcg	11	11	TRUE	FALSE	NA
1675	1674	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	NIT	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	64	64	TRUE	FALSE	NA
1676	1675	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_ESCHR_COLI	2	NTR	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	15	15	TRUE	FALSE	NA
1677	1676	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_ESCHR_COLI	2	NTR	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	16	16	TRUE	FALSE	NA
1678	1677	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_ESCHR_COLI	2	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	17	FALSE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
1679	1678	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_ESCHR_COLI	2	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	16	FALSE	FALSE	NA
1680	1679	EUCAST 2025	human	human	DISK	NA	B_ESCHR_COLI	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	18	18	FALSE	FALSE	[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.
1681	1680	EUCAST 2025	human	human	MIC	NA	B_ESCHR_COLI	2	TGC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.
1682	1681	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	AMC	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	23	23	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1683	1682	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	AMC	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1684	1683	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	AMP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	27	27	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1685	1684	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	AMP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1686	1685	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	AMX	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1687	1686	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	30	30	FALSE	FALSE	[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.
1688	1687	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	CLI	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1689	1688	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1690	1689	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	ETP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1691	1690	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	36	36	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1692	1691	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	IPM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1693	1692	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	35	35	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1694	1693	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	MEM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.03	0.03	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1695	1694	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	MTR	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	30	30	FALSE	FALSE	NA
1696	1695	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	MTR	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1697	1696	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	PEN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	1 unit	25	25	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1698	1697	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	PEN	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1699	1698	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	SAM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	10/10 mcg	33	33	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1700	1699	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	SAM	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.
1701	1700	EUCAST 2025	human	human	DISK	NA	B_FSBCTR_NCRP	2	TZP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	30/6 mcg	32	32	FALSE	FALSE	[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.
1702	1701	EUCAST 2025	human	human	MIC	NA	B_FSBCTR_NCRP	2	TZP	Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
1703	1702	EUCAST 2025	human	human	MIC	NA	B_HLCBCT_PYLR	2	AMX	H.pylori (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1704	1703	EUCAST 2025	human	human	MIC	NA	B_HLCBCT_PYLR	2	CLR	H.pylori (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1705	1704	EUCAST 2025	human	human	MIC	NA	B_HLCBCT_PYLR	2	LVX	H.pylori (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1706	1705	EUCAST 2025	human	human	MIC	NA	B_HLCBCT_PYLR	2	MTR	H.pylori (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	FALSE	FALSE	NA
1707	1706	EUCAST 2025	human	human	MIC	NA	B_HLCBCT_PYLR	2	RIF	H.pylori (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1708	1707	EUCAST 2025	human	human	MIC	NA	B_HLCBCT_PYLR	2	TCY	H.pylori (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1709	1708	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	15	15	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1710	1709	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	50	15	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1711	1710	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1712	1711	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	AMC	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	2	FALSE	FALSE	[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1713	1712	EUCAST 2025	human	human	DISK	indications other than endocarditis and meningitis	B_HMPHL_INFL	2	AMP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	18	18	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
1714	1713	EUCAST 2025	human	human	MIC	indications other than endocarditis and meningitis	B_HMPHL_INFL	2	AMP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
1715	1714	EUCAST 2025	human	human	MIC	indications other than endocarditis and meningitis	B_HMPHL_INFL	2	AMX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
1716	1715	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	AMX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	2	FALSE	FALSE	[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.
1717	1716	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CFM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	26	26	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1718	1717	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CFM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1719	1718	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CHL	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	28	28	FALSE	FALSE	[1] For chloramphenicol treatment in meningitis, see table of dosages.
1720	1719	EUCAST 2025	human	human	DISK	Topical	B_HMPHL_INFL	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	28	28	FALSE	FALSE	NA
1721	1720	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CHL	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] For chloramphenicol treatment in meningitis, see table of dosages.
1722	1721	EUCAST 2025	human	human	MIC	Topical	B_HMPHL_INFL	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1723	1722	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CIP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	32	32	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1724	1723	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CIP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.03	0.03	FALSE	FALSE	NA
1725	1724	EUCAST 2025	human	human	MIC	Topical	B_HMPHL_INFL	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1726	1725	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CPD	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	26	26	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1727	1726	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CPD	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1728	1727	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CPT	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.03	0.03	FALSE	FALSE	NA
1729	1728	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CRO	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	32	32	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1730	1729	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CRO	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1731	1730	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CTB	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	25	25	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1732	1731	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CTB	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1733	1732	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CTX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	27	27	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1734	1733	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CTX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1735	1734	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	27	25	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1736	1735	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	27	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1737	1736	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	2	FALSE	FALSE	NA
1738	1737	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	CXM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	1	FALSE	FALSE	NA
1739	1738	EUCAST 2025	human	human	DISK	pneumonia	B_HMPHL_INFL	2	CZT	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30/10 mcg	23	23	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.
1740	1739	EUCAST 2025	human	human	MIC	pneumonia	B_HMPHL_INFL	2	CZT	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[3] See table of dosages for dosing for different indications.
1741	1740	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	DOR	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	23	23	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1742	1741	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	DOR	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1743	1742	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	DOX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
1744	1743	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	ETP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	23	23	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1745	1744	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	ETP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1746	1745	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	FEP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	28	28	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1747	1746	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	FEP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1748	1747	EUCAST 2025	human	human	MIC	Topical	B_HMPHL_INFL	2	GEN	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1749	1748	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	IPM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	20	20	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1750	1749	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	IPM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1751	1750	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	LVX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	30	30	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1752	1751	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	LVX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1753	1752	EUCAST 2025	human	human	MIC	Topical	B_HMPHL_INFL	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1754	1753	EUCAST 2025	human	human	DISK	indications other than meningitis	B_HMPHL_INFL	2	MEM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	20	20	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1755	1754	EUCAST 2025	human	human	MIC	indications other than meningitis	B_HMPHL_INFL	2	MEM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1756	1755	EUCAST 2025	human	human	MIC	meningitis	B_HMPHL_INFL	2	MEM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1757	1756	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	MFX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	28	28	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1758	1757	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	MFX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1759	1758	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	MNO	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	24	24	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
1760	1759	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	MNO	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
1761	1760	EUCAST 2025	human	human	DISK	screen only	B_HMPHL_INFL	2	NAL	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	23	23	FALSE	FALSE	[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.
1762	1761	EUCAST 2025	human	human	DISK	Topical	B_HMPHL_INFL	2	NAL	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	23	23	FALSE	FALSE	[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).
1763	1762	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	OFX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	30	30	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1764	1763	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	OFX	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1765	1764	EUCAST 2025	human	human	MIC	Topical	B_HMPHL_INFL	2	OFX	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1766	1765	EUCAST 2025	human	human	DISK	screen only	B_HMPHL_INFL	2	PEN	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	1 unit	12	12	FALSE	FALSE	[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1767	1766	EUCAST 2025	human	human	DISK	for prophylaxis only	B_HMPHL_INFL	2	RIF	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	18	18	FALSE	FALSE	NA
1768	1767	EUCAST 2025	human	human	MIC	for prophylaxis only	B_HMPHL_INFL	2	RIF	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1769	1768	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	SAM	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.
1770	1769	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	SXT	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	23	20	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1771	1770	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	SXT	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	1	FALSE	FALSE	[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1772	1771	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	TCY	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	25	25	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
1773	1772	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	TCY	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
1774	1773	EUCAST 2025	human	human	MIC	Topical	B_HMPHL_INFL	2	TOB	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	FALSE	FALSE	NA
1775	1774	EUCAST 2025	human	human	DISK	NA	B_HMPHL_INFL	2	TZP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	30/6 mcg	27	27	FALSE	FALSE	[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.
1776	1775	EUCAST 2025	human	human	MIC	NA	B_HMPHL_INFL	2	TZP	H.influenzae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.
1777	1776	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	AMC	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	22	22	FALSE	FALSE	NA
1778	1777	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	AMP	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	[2] Susceptibility can be inferred from benzylpenicillin susceptibility.
1779	1778	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	AMX	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	[2] Susceptibility can be inferred from benzylpenicillin susceptibility.
1780	1779	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	AZM	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Susceptibility can be inferred from erythromycin susceptibility.
1781	1780	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	CIP	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	28	28	FALSE	FALSE	NA
1782	1781	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	CIP	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1783	1782	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	CLR	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Susceptibility can be inferred from erythromycin susceptibility.
1784	1783	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	CRO	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	30	30	FALSE	FALSE	NA
1785	1784	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	CRO	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	NA
1786	1785	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	CTX	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	27	27	FALSE	FALSE	NA
1787	1786	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	CTX	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1788	1787	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	CXM	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	29	29	FALSE	FALSE	NA
1789	1788	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	CXM	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1790	1789	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	DOX	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.
1791	1790	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	ERY	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	20	20	FALSE	FALSE	NA
1792	1791	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	ERY	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1793	1792	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	LVX	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	28	28	FALSE	FALSE	NA
1794	1793	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	LVX	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1795	1794	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	MEM	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	30	30	FALSE	FALSE	NA
1796	1795	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	MEM	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.03	0.03	FALSE	FALSE	NA
1797	1796	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	PEN	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	1 unit	25	25	FALSE	FALSE	NA
1798	1797	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	PEN	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.03	0.03	FALSE	FALSE	NA
1799	1798	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	RIF	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	20	20	FALSE	FALSE	NA
1800	1799	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	RIF	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1801	1800	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	SXT	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	28	28	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1802	1801	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	SXT	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1803	1802	EUCAST 2025	human	human	DISK	NA	B_KGLLA_KING	2	TCY	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	28	28	FALSE	FALSE	NA
1804	1803	EUCAST 2025	human	human	MIC	NA	B_KGLLA_KING	2	TCY	K.kingae (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1805	1804	EUCAST 2025	human	human	DISK	NA	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	19	FALSE	FALSE	NA
1806	1805	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	19	19	TRUE	FALSE	NA
1807	1806	EUCAST 2025	human	human	MIC	NA	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	8	FALSE	FALSE	NA
1808	1807	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_KLBSL	3	CXM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	TRUE	FALSE	NA
1809	1808	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_KLBSL	3	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	20	FALSE	FALSE	[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
1810	1809	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_KLBSL	3	CZO	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	4	FALSE	FALSE	[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported "susceptible, increased exposure” (I) to cefazolin.
1811	1810	EUCAST 2025	human	human	DISK	uncomplicated UTI only	B_KLBSL	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	15	15	TRUE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
1812	1811	EUCAST 2025	human	human	MIC	uncomplicated UTI only	B_KLBSL	3	MEC	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	8	8	TRUE	FALSE	[6] Agar dilution is the reference method for mecillinam MIC determination.
1813	1812	EUCAST 2025	human	human	DISK	infections originating from the urinary tract	B_KLBSL	3	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	17	FALSE	FALSE	[F] Ignore isolated colonies within the inhibition zone.
1814	1813	EUCAST 2025	human	human	MIC	infections originating from the urinary tract	B_KLBSL	3	TEM	Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	16	FALSE	FALSE	NA
1815	1814	EUCAST 2025	human	human	DISK	all indications	B_LISTR_MNCY	2	AMP	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	2 mcg	16	16	FALSE	FALSE	NA
1816	1815	EUCAST 2025	human	human	MIC	all indications	B_LISTR_MNCY	2	AMP	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1817	1816	EUCAST 2025	human	human	DISK	indications other than meningitis	B_LISTR_MNCY	2	ERY	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	25	25	FALSE	FALSE	NA
1818	1817	EUCAST 2025	human	human	MIC	indications other than meningitis	B_LISTR_MNCY	2	ERY	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1819	1818	EUCAST 2025	human	human	DISK	all indications	B_LISTR_MNCY	2	MEM	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	26	26	FALSE	FALSE	NA
1820	1819	EUCAST 2025	human	human	MIC	all indications	B_LISTR_MNCY	2	MEM	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1821	1820	EUCAST 2025	human	human	DISK	indications other than meningitis	B_LISTR_MNCY	2	PEN	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	1 unit	13	13	FALSE	FALSE	NA
1822	1821	EUCAST 2025	human	human	MIC	indications other than meningitis	B_LISTR_MNCY	2	PEN	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	NA
1823	1822	EUCAST 2025	human	human	DISK	all indications	B_LISTR_MNCY	2	SXT	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	1.25/23.75 mcg	29	29	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1824	1823	EUCAST 2025	human	human	MIC	all indications	B_LISTR_MNCY	2	SXT	L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)	NA	0.06	0.06	FALSE	FALSE	[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.
1825	1824	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	AMC	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	2/1 mcg	19	19	FALSE	FALSE	NA
1826	1825	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	AMC	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.
1827	1826	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	AZM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1828	1827	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	CFM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	21	21	FALSE	FALSE	NA
1829	1828	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	CFM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	NA
1830	1829	EUCAST 2025	human	human	DISK	Topical	B_MRXLL_CTRR	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	31	31	FALSE	FALSE	NA
1831	1830	EUCAST 2025	human	human	MIC	Topical	B_MRXLL_CTRR	2	CHL	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	NA
1832	1831	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	CIP	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	31	31	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1833	1832	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	CIP	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1834	1833	EUCAST 2025	human	human	MIC	Topical	B_MRXLL_CTRR	2	CIP	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1835	1834	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	CLR	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1836	1835	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	CRO	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	24	21	FALSE	FALSE	NA
1837	1836	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	CRO	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	2	FALSE	FALSE	NA
1838	1837	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	CTX	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	20	17	FALSE	FALSE	NA
1839	1838	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	CTX	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	2	FALSE	FALSE	NA
1840	1839	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	21	18	FALSE	FALSE	NA
1841	1840	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	50	21	FALSE	FALSE	NA
1842	1841	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	4	8	FALSE	FALSE	NA
1843	1842	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	CXM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.001	4	FALSE	FALSE	NA
1844	1843	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	DOR	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	30	30	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1845	1844	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	DOR	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1846	1845	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	DOX	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
1847	1846	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	ERY	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	15 mcg	23	23	FALSE	FALSE	[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.
1848	1847	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	ERY	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1849	1848	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	ETP	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	29	29	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1850	1849	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	ETP	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.5	0.5	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1851	1850	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	FEP	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	20	20	FALSE	FALSE	NA
1852	1851	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	FEP	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	4	4	FALSE	FALSE	NA
1853	1852	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	IPM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	29	29	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1854	1853	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	IPM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1855	1854	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	LVX	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	29	29	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1856	1855	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	LVX	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1857	1856	EUCAST 2025	human	human	MIC	Topical	B_MRXLL_CTRR	2	LVX	Topical agents (file: Clinical Breakpoint Tables v. 15.0)	NA	0.125	0.125	FALSE	FALSE	NA
1858	1857	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	MEM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	10 mcg	33	33	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1859	1858	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	MEM	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	2	2	FALSE	FALSE	[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.
1860	1859	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	MFX	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	5 mcg	26	26	FALSE	FALSE	[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note
1861	1860	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	MFX	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	0.25	0.25	FALSE	FALSE	NA
1862	1861	EUCAST 2025	human	human	DISK	NA	B_MRXLL_CTRR	2	MNO	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	30 mcg	25	25	FALSE	FALSE	[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.
1863	1862	EUCAST 2025	human	human	MIC	NA	B_MRXLL_CTRR	2	MNO	M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)	NA	1	1	FALSE	FALSE	[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.

The file is too large to be shown. View Raw